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Introduction.
The central nervous system and epigenetic regulation.
Adaptation to the environment is one of the fundamental regulatory
processes in biology. In a changing environment, simple organisms enhance
their chances of survival by high rates of spontaneous mutations and by natural
selection the mutations that better fit the changes will be retained [1]. Natural
selection also affects complex multi cellular organisms. However in these
organisms the rates of maturation and reproduction are much slower so that
changes in the environment outpace genetic evolution. A solution to this
problem is the development of complex physiological and behavioral systems
coordinated by the central nervous system (CNS).
The nervous system permits rapid adaptation by coordinating impulses
from internal and external cues and executes a physiological response that will
7maintain homeostasis [2]. To cope with environmental complexity and
ambiguity, an organism requires mechanisms that allow experience to affect
relatively long-lasting changes in behavior. This mechanism is called learning
[3]. So how does the nervous system generate the diversity in cell types and
connections to respond to environmental changes or experience?
Although somatic mutation has been proposed to generate diversity in
neuronal precursors through retrotransposon hopping as it does in the immune
system it is more likely that permanent changes in gene expression not
involving changes in DNA sequence itself are achieved by modifications of the
chromatin structure. Self-perpetuating changes in the chromatin structure of a
locus that induce long lasting changes in gene expression are referred to as
epigenetic modifications. Epigenetic changes allow genotypically identical cells
to be phenotypically different. Thus the concept of chromatin remodeling
potentially addresses one of the key challenges in neurobiology of how stable
changes in gene expression are induced in neurons and glia in response to
environmental clues. In this view chromatin is a dynamic structure that
potentially can integrate hundreds of signals from the cell surface and effect a
coordinated and appropriate transcriptional response.
Epigenetic modifications.
Chromatin is composed of a complex of DNA, histones and non-histone
proteins in the cell nucleus. The fundamental unit of chromatin is the
nucleosome: 147 base pairs of DNA wrapped around a core histone octamer.
8Each octamer contains two copies of each of the histones H2A,H2B,H3 and H4.
This nucleosome structure allows DNA to be tightly packaged into the nucleus.
Chromatin remodeling affects the DNA-protein interactions to ensure that
appropriate loci remain accessible to the transcriptional machinery with high
spatial and temporal resolution.
One of the best characterized chromatin remodeling mechanisms is the
post-translational modification of histones at distinct amino acid residues in
their N-terminal tails. Such modifications include acetylation, ubiquitylation or
methylation (on lysine and arginine residues), phosphorylation (serine or
threonine) and ADP ribosylation (glutamate residues). DNA methylation is
another important mechanism of epigenetic gene regulation. It occurs by
transfer of a methyl group from S-adenosyl methionine (SAM) to the cytosine in
a CpG dinucleotide. Patterns of DNA methylation are intricately linked to
patterns of histone modification [4].
Epigenetic tagging of DNA: CpG methylation.
One class of epigenetic regulation involves direct chemical modification
to the DNA molecule by addition of a methyl group (from S-adenosyl
methionine) to the C5 position of the cytosine in a CpG dinucleotide (m5C). This
modification is found in all eukaryotic phyla [5-7] and the fact that the genes
involved in DNA methylation seem to be conserved suggests that proficiency for
cytosine methylation is ancestral. However there are numerous species which
show no or little methylation, like Saccharomyces sp. and Caenorhabditis
9elegans. Drosophila melanogaster is reported to have a trace amount of
methylation only in early embryos [8]. Nevertheless the existence of trace of
methylation in Drosophila m. and S. Pombe and the fully functional methylation
system in other insects and fungi suggests that some evolutionary lineages have
lost methylation as opposed to never having had it.
DNA methylation was first noticed by Hotchkiss in 1948  in calf thymus
DNA [9]. It was then discovered that the sequences of satellite DNA and parasitic
elements (such as long interspersed transposable elements (LINES), short
interspersed transposable elements (SINES) and endogenous retroviruses)
contained CpG dinucleotides where the cytosine were methylated [10, 11].
Subsequently a role for this nucleotide signature was suggested by the
observation that gene expression levels inversely correlated with the density of
methylated CpG dinucleotides. These observations were made both in the
developmentally regulated genes [12, 13] [14, 15], and in viral elements [16].
Cytosine 5 methylation of eukaryotic genomes was then causally associated with
repression of transcription. Consistent with this view, pharmacological agents
that reduce the level of cytosine methylation were found to increase gene
expression [17]. Importantly, it was also noticed that these treatments lead to
dramatic changes in culture phenotypes reminiscent of differentiation [18]
which suggested that methylation of genes could be regulating development.
The palindromic CpG dinucleotide provides a semi conservative mechanism for
the maintenance of methylation, and thus regulatory information, through
replication [19]. Sites are symmetrically methylated prior to DNA synthesis [20],
replication then renders them hemimethylated by incorporation of unmethylated
cytosines into the daughter strands, and the sites are subsequently restored to
10
full methylation by the maintenance DNA methyl transferases. Subsequent
transfection experiments have demonstrated that arbitrary methylation patterns
are maintained through cell division, confirming the clonal heritability of
methylation patterns [21].
Maintenance and establishment of DNA methylation is accomplished by
at least three independent catalytically active DNA methyltransferases: Dnmt 1,
Dnmt3a and Dnmt3b [22, 23]. There are two isoforms of Dnmt1, an oocyte
specific isoform (Dnmt1o) and a somatic isoform. Somatic Dnmt1 is believed to
be responsible for copying methylation patterns during DNA replication, while
the Dnmt3 enzymes (Dnmt3a, 3b, 3l and a number of isoforms) are required for
the de- novo methylation that occurs after implantation and methylation that is
found on newly integrated retroviral sequences in mouse ES (embryonic stem)
cells [22, 24], and for establishment of imprints (Dnmt3l) [25]. DNA
methyltransferase 3a (Dnmt3a) and its regulatory factor, DNA methyltransferase
3-like protein (Dnmt3L), are both required for the de novo DNA methylation of
imprinted genes in mammalian germ cells. Dnmt3L interacts specifically with
unmethylated lysine 4 of histone H3 and induces de novo DNA methylation by
recruitment or activation of DNMT3a2 [26, 27]. The essential role of DNA
methylation in mammalian development is highlighted by the fact that mutant
mice lacking each of the enzymes die either during early embryonic
development (Dnmt1 and Dnmt3b) or shortly after birth (Dnmt3a) [24, 28]. The
knock out of Dnmt3l leads to male infertility and failure to establish imprinting
in female eggs [29]. DNA methyltransferase 2 (Dnmt2) has a dual-specificity, a
weak DNA methyltransferase and novel tRNA methyltransferase activity.
However, its biological function is still unknown.
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In human somatic cells, m5C accounts for ~1% of total DNA bases and
therefore affects 70-80% of all CpG dinucleotides in the genome [30]. In mouse
somatic dells, during a discrete phase of early development, methylation levels
decline sharply to 30% of the typical somatic level [31] [32]. De novo
methylation restores normal levels by the time of implantation.
The most striking feature of vertebrate DNA methylation patterns is the
presence of CpG islands, which are unmethylated GC-rich regions that possess
high relative densities of CpG and are positioned at the 5’ end of many human
genes. Computational analysis of the human genome sequence predicts 29000
CpG islands [33] [34]. Earlier studies estimated that 60% of all human genes are
associated with a CpG island, the great majority of which are unmethylated at all
stages of development and in all tissue types [35]. Because many CpG islands
are located at genes that have a tissue restricted expression pattern, it follows
that CpG islands can remain methylation free even when their associated genes
are silent. For example the tissue specific human a-globin [36] gene and a-2(1)
collagen gene [37] have CpG islands that remain unmethylated in all tested
tissues regardless of expression.  A small but significant proportion of CpG
islands become methylated during development, and when this happens the
associated promoter is stably silent. In fact, this developmentally programmed
methylation of CpG islands is involved in genomic imprinting and X-
chromosome inactivation. These de-novo methylation events occur in germ cells
or in the early embryo [38], suggesting that de novo methylation is particularly
active at these stages. There is evidence, however, that de novo methylation can
also occur in adult somatic cells. A significant fraction of all human CpG islands
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are prone to progressive methylation in certain tissues during aging or in
abnormal cells such as cancers [39] and permanent cell lines [40] [41].
Methyl CpG binding Proteins.
There are several potential mechanisms that might lead to transcriptional
repression at methylated loci. For example certain transcription factors are
unable to bind to their recognition sites when 5-methyl cytosine occurs within a
critical base (e.g. myc, E2F, NF-kB). Or DNA methylation might conceivably
result in structural effects on local chromatin architecture (e.g. CTCF insulator at
the Igf2/H19 locus) by influencing nucleosome position or stability, or by
affecting higher order chromatin structure. While these are likely to be
biologically significant regulatory mechanisms in some cases, it is believed that
the repressive effects of DNA methylation result mostly from selective
recognition of the 5-methyl CpG dinucleotide by a conserved family of proteins,
the methyl CpG-binding domain (MBD) family (figure 1).
The first evidence of the existence of CpG binding proteins was reported
in the late 1980s’ when it was shown that the majority of m5C but not adjacent
sequences were specifically protected from nucleases [42]. Then an
electrophoretic mobility shift assay was used to demonstrate a m5C specific
binding activity in mouse tissue: only symmetrically methylated probes were
shifted, and the binding could be competed only by artificially methylated DNA
or mouse genomic DNA [43]. This activity, called MeCP1 (   Methyl   CpG-binding
P  rotein 1) remained enigmatic for several years. Subsequently a second methyl
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CpG binding (MeCP2) protein was identified and cloned [44]. This protein was
found to bind with high affinity and specificity to a single symmetrically
methylated CpG and to co localize with heterochromatin rich areas in the
nucleus of mouse cells [45, 46]. Further characterization showed that this was
not responsible for the (still uncloned) MeCP1 activity. Domain mapping of
MeCP2 identified an 85 amino acid domain which could by itself bind specifically
to sequences containing a single methylated CpG with nanomolar affinity [47].
The sequence of the methyl CpG binding domain (MBD) of MeCP2 was used to
identify a number of related domains in the mammalian genome which were
named MBD1-4 [48]. MBD2 was found to be responsible for the methyl-CpG-
binding activity of the MeCP1 complex [49]. Apart from MBD3, these proteins
have been shown to have specific methyl CpG binding activities. Recently a
novel protein, Kaiso, was identified as a methyl CpG binding protein even
though this protein lacks a classical MBD but appears to bind specifically to
methylated DNA via a zinc finger domain [50]. Several MBD proteins have been
reported to interact with histone deacetylases (HDACs) as well as histone
methyltransferases. MeCP2 has been shown to interact with the Sin3/HDAC co
repressor complex and Brahma, as well as with the histone H3 lysine-9
methyltransferase, Suvar 3-9, although these interactions may not be stable
[51]. MBD2 and MBD3 have been identified as core subunits of the Mi-2/NuRD
complex, whereas Kaiso is part of the HDAC-containing N-CoR complex that
plays an important role in transcriptional regulation by nuclear hormone
receptors. These findings show a functional link between DNA methylation,
histone deacetylation, and histone methylation and indicate that these
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epigenetic events functionally cooperate to regulate transcription and cellular
memory.
Functions of DNA methylation.
Tissue specific regulation by DNA methylation has been hypothesized by
Riggs [52] and Holliday and Pugh [19]. According to their prediction, tissue
specific genes would be methylated or demethylated according to the
developmental program. This hypothesis is particularly attractive because it
provides a mechanism for controlling gene expression in a tissue specific
manner. Because convincing examples of tissue specific genes that undergo
demethylation during development were absent for many years, this hypothesis
was met with skepticism. However since then many studies have correlated DNA
methylation with the control of cell type specific gene. For example   glial
f ibrillary   acid   protein (Gfap) is implicated in the so-called neurogenic to
gliogenic switch. Gfap is expressed in astroglia but not in neurons, and is
regulated by the transcription factor STAT3, which binds directly to elements in
the Gfap promoter to activate transcription. STAT3 expression alone though is
not sufficient to activate Gfap expression. There are CpG sites in the Gfap
promote that are methylated early in development (E11.5) and then become de-
methylated at E14.5 in cells differentiating to become astroglia [53]. One
differentially methylated CpG lies within the STAT-binding element. Takizawa et
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al. (2001) found that methylation at that site prevents binding by the STAT3 and
is present in neurons but not in glia. As the central nervous system develops,
this CpG site becomes de-methylated in cells differentiating along the glial
lineage [54]. Moreover, cultured neuron precursor cells lacking Dnmt1 become
hypomethylated and differentiate prematurely in astrocites [55]. Consistent with
these observations, cervical spinal cord from Dnmt1 mutant early embryos (E15
and E18) exhibit enhanced staining of glial markers such as Gfap and S100b.
 Another example of epigenetic regulation in neural differentiation is
provided by the Re1-silencing transcription factor (REST/NSRF). This factor
binds to neuron-restrictive silencer element (RE1), usually found in promoters of
genes that are expressed specifically in neurons [56]. REST mediated silencing
of neuronal–specific genes occurs in conjunction with CoREST [57], which
recruits additional silencing machinery including the methyl DNA binding
protein MeCP2 and the histone H3 K9 methyltransferases G9a and SuVar39H
[58]. Targets of REST are important neuronal house keeping genes such as
sodium channels (Nach typeII/Nav1.2), synaptic vesicle proteins, and
neurotransmitter receptors. The mechanism of action of the REST complex
differs in different cell types and developmental stages. In embryonic stem cells
REST utilizes a repression mechanism independent of histone H3 methylation
and DNA methylation. When ES cells differentiate into neuron progenitors REST
protein is then down-regulated and further differentiation of progenitors to
mature neurons occurs via the loss of REST complex from the RE1 site of
neuronal genes [59, 60]. Some neuronal genes, such as Calbindin and brain-
derived neurotrophic factor (BDNF), remain expressed at low levels in neurons
due to the continued presence of CoREST and MeCP2 on an adjacent site of
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methylated DNA. Interestingly membrane depolarization increases the level of
expression of the BDNF gene through selective release of MeCP2 but not CoREST
from its methylated site. The persistence of CoREST after REST departure may
provide a mechanism for dynamic recruitment and dismissal of repressor
complexes required for plasticity in mature neurons [59].
Genome defense.
Transposable elements comprise as much as 35% of the human genome.
Because they are capable of insertional mutagenesis, generating aberrant
transcripts and improperly activating nearby genes [61, 62], they threaten the
integrity of the host genome. The host’s genome primary mechanism of defense
is CpG methylation of these elements. This modification attracts chromatin
remodeling factors that induce a silent state [5]. Most of methylated CpG, in the
mammalian genome are found at these repetitive elements, and complete de-
methylation of the genome in mice leads to increased transposon activation
[63]. Retroviruses are also transcriptionally silenced in mammalian embryonic
and hematopoietic stem cells [64] by a mechanism that involves de novo
methylation of cytosine residues in CpG dinucleotides of the integrated
provirus[65].
Genomic imprinting.
A function of cytosine methylation that is specific to mammals and
flowering plants is the regulation of imprinted genes. Imprinted genes are
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differentially expressed depending on the parental origin of the allele. The
maternal or the paternal alleles have differentially methylated regions (DMRs).
The best characterized imprinted genes are involved in fetal growth, though not
all have known function. Perhaps the most widely accepted explanation for the
occurrence of genomic imprinting is the “parental conflict hypothesis “[66].
According to this theory imprinting is the evolutionary result of a conflict
between the paternal and maternal genes, whose expression is either promoting
or limiting embryonic growth, respectively. The father is in theory most
interested in the growth of his offspring, at the expense of the mother, while
the mother is more interested in conserving resources for her own survival while
providing sufficient nourishment for current and future litters. Consistent with
this hypothesis the paternally expressed genes Igf2 and Ins2 enhance growth,
while the maternally expressed genes H19, Igf2r, and p57KIP2 restrict growth.
H19 encodes an untranslated RNA that represses transcription of the Igf2 gene,
which is located about 100 Kb from the H19 locus [67]. A differentially
methylated domain upstream of H19 is methylated during spermatogenesis,
resulting in suppression of paternal expression of H19 [68, 69]. Ig f2 is a
paternally expressed fetal growth factor that is also antagonized by the Igf2r.
Igf2r opposes Igf2 function by acting as a scavenger receptor for Igf2 [70]. The
Igf2r gene acquires methylation marks in intron 2 on the maternal allele during
oogenesis [71]. These marks ensure maternal expression by inhibiting
transcription of Air, the antisense non-coding RNA that is expressed from a
promoter located in intron 2 of the Igf2r gene [72]. Another hypothesis behind
the origin of imprinting is that this phenomenon evolved to silence foreign DNA
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elements. Retrotransposons seem to be over represented around imprinted
genes sequences.
Some genetic diseases that map to 15q11 (band 11 of the long arm of
chromosome 15) in humans have abnormal imprinting. This region is
differentially imprinted on the maternal and paternal chromosomes, and both
imprints are needed for normal development. It is possible for an individual to
fail to inherit a properly imprinted 15q11 region due to a deletion of the
imprinted region or less frequently due to uniparental disomy. If neither
chromosome of 15q11 has a paternal imprint, the result is Prader-Willi
syndrome (PWS), while if neither chromosome has the maternal imprint, the
result is Angelman syndrome (AS)[73]. AS is caused by loss of expression of the
E6-associated protein ubiquitin-protein ligase gene (UB3A), which is maternally
imprinted only in the brain. AS is characterized by epilepsy, tremors and
perpetually distorted facial expression. The main cause of PWS is attributed to
the paternally imprinted SNRPN gene, which encodes the expressed SNURF and
SmN spliceosomal proteins (SNRPN-small nuclear ribonucloprotein associated
proteins polypeptide N). PWS is characterized by hypotonia, obesity and
hypogonadism.
X-chromosome inactivation.
DNA methylation is also involved in the silencing of an entire
chromosome in mammals. In each cell in female mammals, one of the two X-
chromosomes undergoes inactivation in order to match the gene dosage of the
single X chromosome in males. This process also relies on DNA methylation.
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Xist, which encodes an untranslated RNA that is involved in X-inactivation, is
unmethylated on the inactive X and is methylated on the active X-chromosome.
Xist RNA coats the chromosome from which it is transcribed and through a still
unclear mechanism contributes to silencing the genes on that chromosome [74].
The maintenance of the silent state on the inactive X chromosome requires
methylation [75] [76]. The existence of genes along the inactive X that escape
silencing accounts for the defects seen in humans who have an abnormal
numbers of the X chromosomes, such as Turner syndrome (X0) or Klinefelter
syndrome (XXY). Theoretically, X-inactivation should eliminate the differences in
gene dosage between affected individuals and individuals with a normal
chromosome complement, but in affected individuals the dosage of these non-
silenced genes will differ as they escape X-inactivation.
Cancer.
The signal encoded by methylation of CpG dinucleotides is rather
important, so it is at first surprising to note that this dinucleotide is actually
underrepresented in 80% of the mammalian genome. This phenomenon is due
to the mutagenic nature of CpG methylation: whereas spontaneous deamination
of cytosine leads to uracil, deamination of 5-methyl cytosine yields thymine.
Since the repair mechanism for G-U base pairs are more efficient than for G-T
base pairs, non essential methylated CpGs are frequently mutated, resulting in
their under-representation in the genome [77, 78]. (an exception to this are
CpG islands as discussed earlier).
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Most human cancers display genome wide hypomethylation and
concomitant promoter specific hypomethylation of tumor suppressor genes [79-
81]. One problem with the idea that alterations in DNA methylation underlie
cancer is that no mutations in the recognition machinery have been identified in
human cancer. On the other hand there is convincing evidence that constitutive
epigenetic alterations are linked to increased cancer risk. An example of this is
Beckwith-Wiedemann syndrome, which leads to a 800 fold increased risk of
embryonic tumor. Loss of imprinting (LOI) of Igf2 is specifically associated with
increased cancer risks in children with Beckwith-Wiedemann syndrome. LOI of
Igf2 is also found in adults at a frequency of 5-10%, and it is associated with a
5-fold increase in frequency of malignant or benign colorectal neoplasms.
Generation of mice carrying a hypomorphic allele for Dnmt1
demonstrated that global hypomethylation resulted in aggressive T cell
lymphomas that displayed a high frequency of chromosome 15 trisomy. These
results indicated that DNA hypomethylation plays a causal role in tumor
formation, possibly by promoting chromosomal instability.
Using conditional inactivation of Dnmt3b in Apc min/+ mice, our lab has
demonstrated that loss of Dnmt3b has no impact on microadenoma formation,
which is considered the earliest stage of intestinal tumor formation. However we
observed a significant decrease in formation of macroscopic colonic adenomas.
Many large adenomas showed regions with Dnmt3b inactivation, indicating that
Dnmt3b is required for initiation of macroscopic adenomas but is not required
for their maintenance [82]. Consistent with the notion that both promoter
hypomethylation and genome wide hypomethylation are functionally important
in tumorigenesis, genetic or pharmacologic reduction of DNA methylation levels
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results in suppression or promotion of tumor incidence, respectively, depending
on the tumor cell type. For instance, DNA hypomethylation promotes tumors
that rely predominantly on loss of heterozygosity (LOH) or chromosomal
instability mechanisms, whereas loss of DNA methylation suppresses tumors
that rely on epigenetic silencing. Apc min/+ mice were used to investigate the
effect of hypomethylation on intestinal and liver tumor formation. Intestinal
carcinogenesis in Apc min/+ mice occurs in two stages, with the formation of
microadenomas leading to the development of macroscopic polyps. Using a
Dnmt1 hypomorphic allele to reduce genome methylation Yamada et al. [83]
showed an elevated incidence of microadenomas associated with LOH at the Apc
locus. In contrast the incidence and growth of macroscopic intestinal tumors in
the same animals was strongly suppressed. These findings suggest a dual role
for DNA hypomethylation in suppressing later stages of intestinal tumorigenesis
by promoting early lesions in the colon and liver through an LOH mechanism.
Evidence for a function of DNA methylation in the adult CNS.
DNA methylation provides a mode of gene regulation that is maintained
through mitosis, providing a mechanism for heritable transcriptional control
through development. Are these epigenetic mechanisms also operable in non-
dividing, terminally differentiated cells in the adults CNS?
There is a considerable body of evidence, although indirect, implicating
the disruption of epigenetic mechanisms as a causal basis for human cognitive
disorders. For example, two well characterized disorders caused directly by
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improper setting or reading of DNA methylation signals are Rett syndrome and
Fragile X syndrome.
Rett syndrome involves a mutation of the methyl CpG-binding protein 2
(MECP2)gene, which encodes a protein that binds to methylated DNA sequences.
In Rett syndrome, DNA methylation patterns are laid out normally but epigenetic
silencing is impaired because of failure of the mutated MECp2 protein to
properly recognize this mark. Rett syndrome is an X-linked, pervasive mental
retardation disorder, with a prevalence of 1 in 10000 live female births, which is
associated with microcephaly and severe cognitive decline.
Fragile X syndrome, also X-linked mental retardation disorder, is brought
about by an abnormal expansion of repeated trinucleotide sequences within one
of two Fragile genes FMR1 and FMR2 [84, 85]. The genes each contain a
polymorphic trinucleotide repeat (CGG or CCG) in their 5’ untranslated region.
Normally there are 6-50 of these repeats while in Fragile X patients there are up
to 230 repeats. The expansion of these repeats results in hypermethylation and
transcriptional silencing of the FMR and surrounding genes.
Schizophrenia is a serious disorder of cognition and behavior. A large
amount of data indicates that deficiencies in the extra cellular matrix protein
reelin are responsible for the etiology of schizophrenia [86]. The promoter of
reelin contains several sites for DNA methylation, and inhibitors of histone
deacetylase and DNA methyltransferase activities increase expression of reelin,
indicating that an epigenetic mechanism governs the expression of this protein
[87].
When considering these cases, it is important to distinguish between the
developmental need for epigenetic mechanisms that allow formation of a normal
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nervous system versus an ongoing need for these epigenetic modifications
involved in the cognitive process and the normal functioning of the adult brain.
Most of the attention so far has focused on the role of epigenetics in
development; however more and more experimental evidence implicates an
ongoing and active role for epigenetic mechanism in adult brain function.
MeCP2 and Rett Syndrome.
Rett syndrome (OMIM 312750) provided one of the first strong evidences
that epigenetic mechanisms operate in the adult nervous system. The disease
was named after the Austrian physician Andreas Rett who first described it. Two
young girls with a similar and rather peculiar compulsory hand movement had
caught his attention among a group of patients sitting in his waiting room. He
followed the two girls’ physical and behavioral development and published (in
German) a short report on the Viennese Medical Journal [88]. The paper and the
condition it described were virtually overlooked until Hagberg and colleagues
reported in “Annuals of Neurology“ of 35 European girls with Rett Syndrome (RS)
and described them as follows: “After normal general and psychomotor
development up to the age of 7 to 18 months, developmental stagnation
occurred, followed by rapid deterioration of higher brain functions. Within one-
and-a-half years this deterioration led to severe dementia, autism, loss of
purposeful use of the hands, jerky truncal ataxia, and acquired microcephaly.
The destructive stage was followed by apparent stability lasting through
decades. Additional insidious neurological abnormalities supervened, mainly
spastic parapareses, vasomotor disturbances of the lower limbs, and epilepsy.
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Prior extensive laboratory investigations have not revealed the cause. The
condition is similar to a virtually overlooked syndrome described by Rett in the
German literature. The exclusive involvement of females, correlated with
findings in family data analyses, suggests a dominant mutation on one X
chromosome that results in affected girls and nonviable male hemizygous
conceptuses.” [89]. Ten years later the mutation causing RS was located to Xq28
by exclusion mapping studies [90]. Finally in 1999 Amir et al. pinpointed the
mutation to the methyl-CpG-binding protein 2 (MECP2) locus as the cause of
some cases of RTT [91] leading to this unexpected conclusion: “Our study […]
points to abnormal epigenetic regulation as the mechanism underlying the
pathogenesis of RTT. By 2001 mutations in the MECP2 gene were identified in
72% of patients with classical RTT and one third of atypical cases [92]. Over the
past few years, more that 2,000 mutations have been reported in females with
Rett syndrome [93-96]. There are eight common mutations that arise at CpG
hotspots in MECP2 and result in loss of function due to truncated, unstable or
abnormally folded proteins. Genotype-phenotype correlations have given
conflicting results but in general truncating mutations tend to be more severe
than missense mutations [97]. In addition, skewing of X-chromosome
inactivation might modulate the severity of the disorder. More recently, large
rearrangements that involve MECP2, including deletions, were reported in a
significant proportion of patients with Rett syndrome [98]. Altogether,
mutations in the MECP2 gene might account for more than 95% of the sporadic
cases of classical Rett syndrome in females. In almost all cases the mutations
are de-novo, and there is evidence that they might arise on the paternal X
chromosome [99, 100].
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As mentioned above there is a proportion of individuals with clinical
diagnosis of RS that do not appear to have mutation in the MECP2 gene.
Mutations in two other genes CDKL-5 and Netrin-G [101] have been shown to
be associated with a phenotype that strongly overlaps with that of RS. In all the
cases reported CDKL5 mutations have been associated with an early-onset-
seizures variant of RS, the so-called Hanefiled variant. There is some evidence
for a direct interaction between CDKL-5 and MECP2, suggesting the possibility
of a common pathway in the regulation of neuronal cell function, but it remains
to be confirmed how this interaction contributes to the pathogenesis of RS [102,
103]. Conversely MECP2 mutations have also been found in other clinical
phenotypes, including individuals with Angelman-like, non-syndromic X-linked
mental retardation [104] and autism [105].
The symptoms and disease progression.
Classic RS diagnosis is based on a number of criteria first defined by
Hagberg. The necessary criteria for diagnosis are the following: 1) Normal pre
and perinatal history, 2) normal psychomotor development for the first 6
months, 3) normal head circumference at birth followed by 4) postnatal
deceleration of head growth. 5) Subsequent loss of purposeful hand skills
between 6 month and 2 years, 6) evolving social withdraw 7) loss of acquired
speech 8) deterioration of locomotion and cognitive functions. Supportive
diagnostic criteria are also: 1) breathing disturbances during waking hours, 2)
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abnormal muscle tone (dystonia, muscle wasting), 3) disturbed sleep patterns,
4) progressive kyphosis or scoliosis.
Although it was initially believed that the recognizable features of RS
appear after an apparently normal prenatal, perinatal and early infancy period,
more recent studies have clearly shown that even in the first 6 months of life the
female infants display subtle behavioral abnormalities [106, 107]. A general
stagnation of development is followed by the loss of fine and gross motor skills
and intellectual functioning. A more definitive clinical presentation evolves in
stages over a number of years, culminating in motor deterioration and death in
early adulthood. It is clear now that females with RS have a much broader
phenotype than first thought, with a number of variants which can be more
(patients who never go through a period of normal development) or less
(patients with speech preservation and normal head growth) severe symptoms
than these seen in classical RS. Moreover it now known that there exists,
although rarely, males with MECP2 mutation who present a severe neonatal
onset encephalopathy associated with prominent breathing abnormalities [108].
Human pathology.
A characteristic neuroanatomical finding in RS patients is an overall
decrease in brain size that manifest only after 12 months of age. MRI and
autopsy examinations reveal that the brain of Rett syndrome patients is smaller
than age matched controls, and that, unlike the brain in a degenerative disease,
it does not become progressively smaller over time. Moreover, only the brain,
and no other organ, is small, emphasizing the susceptibility of the nervous
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system in the Rett disorder.  Volumetric studies in patients (MRI) show
preferential decrease in prefrontal, posterior and anterior temporal regions. The
neuron’s soma is smaller and there is an accompanying increase in cell density
per unit of volume [109] but the total number of neurons appears normal. No
neurodegeneration has ever been observed [110] and there seem to be no
problems with neuronal migration [111].
According to some early reports, there is a selective decrease in dendritic
branching and spine number with a concomitant reduction in cortical thickness
in the same areas where the reduced volume was observed [112-114].
Immunocytochemical studies defined alterations in synaptic sites, early-
response genes and MAP-2 immunoreactivity was altered in selected neuronal
populations. Studies of neurotransmitters expression using various techniques
in diverse brain regions or cerebrospinal fluid have given contrasting results,
with only, the studies on cholinergic neurotransmission showing a consistent
decrease. The hypothesis that neurotransmitters levels are decreased in Rett
syndrome remains attractive, because it explains many of the functional deficits
in Rett syndrome, and suggests a mechanism for defective brain maturation.
However, the measurement of neurotransmitters and the interpretation of the
results is problematic because the studies have included girls and women at
different stages of the Rett disorder using different techniques on different
tissues.
Other genes have been found to have altered expression in post-mortem
tissue from Rett patients, for example mRNA levels for the N-methyl D-
Aspartate (NMDA) type glutamate receptors NR1 subunit and metabotropic
mGluR1 receptor were increased 1.5 folds while synapse related proteins such
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as synapsin II, synaptogirin 3, synaptogamins 1,5 and syntaxin 1a were
decreased [112].
It has to be taken in consideration that all of the data regarding the
dendritic morphology and the synaptic markers come from autopsies of small
cohorts of patients at different ages and stages of the disease published by two
research groups. In contrast to the finding in humans, morphological studies on
fully symptomatic MeCP2 mutant mice [115] [116] did not reveal any dendritic
abnormality or misexpression of synaptic markers. Conversely Fukuda et al.
[117] noticed a reduction in cortical thickness and reduced spine counts in the
MeCP2 null mice [118]. So, in our opinion it remains an open question of
whether the morphological abnormalities observed in post-mortem human
tissues are the cause or the consequence of the functional defects in RS.
Cause of death in patients.
Rett patients (females) might be able to survive into middle and old age
but their life expectancy is reduced by a higher incidence (26%) of sudden death
(SD) compared to that seen in the normal population (1/100K). Possible causes
of SD in RS are autonomic failures, apnoea and cardiac arrhythmias. In 1997
histological examination of 6 postmortem samples from Rett patients who died
of SD revealed some anatomic abnormalities. In contrasts a more recent study
involving 32 Rett syndrome girls evaluated by echocardiography did not show
any cardiomyopathy [119]. Around 20% of the patients show a significant
prolongation of QT corrected intervals (QT interval is a measure of the time
between the start of the Q wave and the end of the T wave in the heart's
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electrical cycle). The cause of this abnormality is still not clear. There does not
seem to be a sympathetic hyperactivity but low NGF (Nerve Growth Factor)
plasma levels were observed suggesting a possible role for neurotrophic factors
in the pathology. Another 26% of the deaths in RS girls is attributed to sudden
respiratory arrhythmias [120]. Breathing seems normal during sleep but can
switch from highly irregular to regular breathing during wakefulness [121],
which would suggest a disturbed cortical rather than a brainstem problem. This
symptom might also be caused by an improper expression of neuromodulators
in the medulla [122]. The bioaminergic alterations observed in Mecp2-deficient
mice could be responsible for their respiratory disorders and compensating for
these bioaminergic deficits could alleviate their respiratory disorders.
Structure of the mouse Mecp2 gene.
The Mecp2 gene which is located on the X-chromosome (Xq28) spans
over ~ 50 Kb. It is composed of 4 exons which are alternatively spliced, creating
two transcripts that produce two different protein (MeCP2e1 and MeCP2e2) that
have different ATGs and differ by only 17 amino acids at the N-terminus.
Although both forms are highly expressed in the brain, they differ in
translational efficiency and are expressed at different amounts in various
tissues, with MeCP2e1 being more prevalent in the brain, thymus and lung
[123]. Additional Mecp2 transcripts with 3’ UTRs of different length are also
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produced by the use of alternative poly-adenylation sites. Their expression also
varies between tissues and developmental stages (figure 2).
Structure of the protein and expression pattern.
The Mecp2 gene encodes a ~500 amino acid protein that has three
recognizable domains. A methyl binding domain (MBD) that mediates the DNA-
protein interaction, a transcription repression domain (TRD) that mediates
protein-protein interaction and a third domain in the carboxy terminus that has
homology to the members of the forkhead family of transcription factors but
has no known function in MeCP2 [124]. MeCP2 has an important role in
interpreting the methylation mark on DNA, but how does this translate into
functional consequences? Several different mechanisms have been proposed.
First, MeCP2 binding might influence local nucleosome position; alternatively
MeCP2 could serve to recruit a enzymatic machinery which is responsible for the
stable transcriptional repression. The transcriptional repressor domain (TRD)
has been shown to interact with various co-repressor complexes such as Sin3a,
ci-Ski, and N-Cor [125-127]. These silencing complexes include histone
methyltransferases [128] and histone deacetylases (HDAC1 and 2) [126].  MECP2
transcriptional repressor activity is in fact sensitive to HDAC inhibitors, but there
is also a MeCP2-dependent repression that is refractory to HDAC inhibitors,
suggesting that some other mechanism might be involved. Harikrishnan et al.
reported an interaction between MeCP2 and the SWI/SNF chromatin-remodeling
complex [129] although this finding has been recently disputed [130].The
SWI/SNF complex uses energy from ATP hydrolysis to alter local chromatin
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structure [131]. Interestingly  MBD2 and MBD3 also, have been found in a stable
complex with a chromatin-remodeling ATPase similar to SWI/SNF [131].Another
interesting mechanism of action for MeCP2 mediated silencing was proposed in
2005 by Horike et al. The group has found that MeCP2 binds to a cluster of
imprinted genes comprising Dlx5 and DLX6 on chromosome 6 and induces the
formation of a 11kb long silent chromatin loop [132]. Moreover Dlx5 and Dlx6
were found upregulated (having biallelic instead of monoallelic expression) in
MeCP2 KO mice and in lymphoblastoid cells of Rett syndrome patients. Dlx5
regulates production of enzymes that synthesize gamma-aminobutyric acid
(GABA); therefore loss of imprinting of Dlx5 may alter GABAergic neuron activity
an in individuals with Rett syndrome. (An increased density of GABA receptors in
Rett syndrome patients was reported years before [133]) . The conclusion from
these observations was that formation of a silent-chromatin loop is the
mechanism underlying gene regulation by MeCP2. However, once again, these
results turned out difficult to reproduce, to the point that it is even debatable
whether in human cells Dlx5 and Dlx6 are subject to imprinting at all [134].
There is little correlation between the levels of Mecp2 mRNA and protein
suggesting that regulation of this gene is at the translational level [135, 136].
The protein is expressed in several tissues in adult mice; in particular it is high
in brain, lung and spleen, lower in heart and kidney and barely detectable in
liver, stomach and small intestine [135, 136] (figure 3).
In the mouse brain MeCP2 is expressed strongly in neurons (a weak
expression has been reported in astroglia) and its expression starts at around
E18.5 and correlates with the maturation of the nervous system. Ontogenically
older structures such as brain stem and spinal cord express MeCP2 before
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newer structures such as hippocampus and cerebral cortex. In the cortex MeCP2
first appears in the Cajal-Retzius cells, then in the deeper and more mature
cortical layers and progressively comes on in the neurons of the more
superficial layers. Eventually all neurons become positive although differences in
the intensity of the staining persist among different neuronal populations. This
suggests that MeCP2 becomes abundant only when a neuron has reached a
certain stage of maturity. [135, 136] (figure 4).
Interestingly, in the human brain, the number of MeCP2 positive neurons
increases dramatically through gestation and continues to increase in the cortex
from birth until 10 years of age. This difference between the mouse and human
expression in the brain could represent the extended period of developmental
plasticity in humans, in which neurons have not achieved their fully
differentiated state [136] Examples of experience-dependent plasticity are
abundant for several areas of the brain like visual, auditory and somatosensory
cortex [137]. The cellular basis of this plasticity is thought to involve several
aspects of neuronal physiology like synaptogenesis, myelination, and neuronal
transmitter expression. Also in humans the time course of glucose utilization
and synaptogenesis increases between birth and 4 years, followed by a plateau
until age 10, after which it slowly declines during adolescence to adult levels
[138]. The correlation between MeCP2 expression, glucose utilization,
synaptogenesis and experience-dependent plasticity in humans is again very
suggestive of a role for MeCP2 in very mature neurons. Indeed several studies
conducted in the olfactory bulb [139], hippocampus, and cerebellum [140] in
mice have shown that MeCP2 expression is exactly timed with synapse
formation. Indeed lower levels of several dendritic specific and synaptic proteins
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have been found in brain tissue from patients with Rett syndrome [141] [112,
142, 143]. Yet it is not clear what it is the functional relevance of these
observations.
Mouse models for Rett syndrome.
The interest in creating a transgenic mouse with a deletion of the Mecp2
gene arose well before the discovery that mutations in this locus were
responsible for Rett syndrome. In 1999 Tate et al., using homologous
recombination created male ES cells with a complete deletion of the Mecp2
coding sequence and showed that these cells were unable to support embryonic
development beyond E8.5-12 (E: embryonic day) [144]. The conclusion was that
MeCP2 and DNA methylation were essential for embryonic development. To
overcome the problems connected with studying an early lethality phenotype
two groups subsequently generated conditional Mecp2 alleles in which exon3
[145] or exon 3 and 4 [118] were flanked by loxP sites. In this set of
experiments the Mecp2 conditional allele was deleted using a Cre recombinase
driven by a promoter (Nestin) that becomes active in neuronal precursors at
around E10.5  (it is also weakly active in kidney, heart, lungs and germ cells).
Both germline and CNS recombined hemizygous null males were derived from
the experiment and surprisingly both sets of mice displayed an almost identical
phenotype. Mecp2 germline and CNS recombined null males (hemizygous) were
born seemingly normal, but developed symptoms between 3 and 8 weeks and
died within 15 weeks. They exhibited severe motor deficits, stereotypic back
limb clasping, abnormalities in gait and grip strength, reduced motor
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coordination, reduced dark cycle locomotor activity, severely impaired swim
performance and they were not fertile. In addition to motor and cognitive
deficits, the nulls exhibited changes such as piloerection, breathing
irregularities, and body tremors that may reflect impaired autonomic
functioning. These motor deficits are consistent with the human pathology of
Rett syndrome; moreover, these behavioral changes are associated with a
significant volumetric reduction in the striatum (29%), the amygdala and the
hippocampus. Surprisingly, in the mice the reduced volumes in two other motor
regions frequently noted in the human pathology, the frontal cortex and
cerebellum, were not observed [141]. However one group has reported
decreased cortical thickness in the motor and somatosensory cortex of the
hemizygous mice with reduced spine density in layer II and III [117]. Female
mice that are heterozygous for MeCP2 were also viable, fertile and seemed
normal until adulthood. However at about 6 months of age these mice began to
show the same neurological symptoms that were seen in the null males.
In another set of experiments the conditional Mecp2 allele was ablated
using a cre recombinase driven by the Cam kinase promoter that is active
postnatally (P0-P15) in the forebrain, hippocampus and brainstem. The
development of these mice (male hemizygous) was normal until 3 months when
some mild symptoms appeared such as ataxia, hypoactivity, and reduced brain
weight [146]. This was the first evidence that MeCP2 is required not only during
neuronal development but also in the mature CNS. The analysis of the
conditional knock out mice was remarkably informative because it demonstrated
that MeCP2 is dispensable for early embryonic development and that a restricted
deletion of MeCP2 in the CNS is sufficient to induce symptoms.
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Because Rett syndrome patients do not carry deletions of the Mecp2
coding sequence but rather have point mutations that cause missense or
premature stop codons, a third mouse model that would better mimic the
human disease was generated in 2001 by Shahbazian et al.[147]. In this model
the MeCP2 protein is truncated after codon 308 (MeCP2308), retaining all the
known functional domains such as the methyl binding domain, the
transcriptional repression domain and the nuclear localization signal.
 MeCP2308 mutants are viable and fertile (both males and females) but at
around 6 months of age exhibit some motor coordination and social interaction
defects. Early experiments performed in Mecp2308/Y mice with mixed genetic
background did not reveal learning abnormalities using the Morris water maze
and fear conditioning tests [147]. Later experiments by Moretti et al. on a pure
inbred strain (129/SvEv) and using a less intense training schedule did instead
show a deficit in learning and memory [115]. (A summary of the mouse models
and their respective features is presented in figure 5).
A poorly understood aspect of RS is the disease progression. Early
development seems relatively normal and, although recent studies have shown
that even in the first 6 months of age RS girls display subtle behavioral
abnormalities, the diagnosis of the disease occurs usually at 1year of age or
later. A long standing question, therefore, has been whether the appearance of
symptoms is the manifestation of irreparable damage to the brain that occurred
during pre and peri natal development or if it is due to the specific requirement
for MeCP2 in mature CNS function. The question is particularly relevant as the
answer will impact the development of a therapy. Would post-natal treatment be
efficacious, at least in principle, or is there need for pre-natal screening?
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Using the mouse models it has been possible to demonstrate that MeCP2
is indeed required in the adult CNS, as shown by the fact that post-natal
deletion (P0-P15) induced the appearance of RS like symptoms. This study,
however, did not rule out the possibility that MeCP2 was also required for
proper neurogenesis and early brain development. In Chapter 1 evidence that
MeCP2 is in fact dispensable for neurogenesis is presented.
Further characterization of the disease progression.
A further question that arises from these experiments is how late in
development or adulthood can reactivation of MeCP2 function lead to rescue of
the symptoms? The presence of largely normal brain architecture and the
absence of neurodegeneration in RS would suggest that no irreparable damage
to the structure has occurred because of MeCP2 deficiency and that once this
function is restored there is the potential for reversal of the symptoms, partial
or complete. Alternatively, MeCP2 might be essential for neuronal function
during a specific time window, after which physiological damage caused by its
absence is irreversible. Evidence that specific reactivation of MeCP2 in the brain
during postnatal development does indeed lead to partial rescue of the RS
phenotype is described in Chapter 2.
Rett syndrome a disease of synapse formation?
Physiological characterization of the MeCP2 null mutant mouse.
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Some of the cognitive and behavioral abnormalities observed in RS
patients have interesting similarities with non-syndromic mental retardation in
males and females [148], mild learning disabilities [149] and autism [105]. So
understanding the role of MeCP2 in normal and pathological brain function
might be informative not only for RS but for other disorders. The development
of mouse models has made possible a more detailed characterization of the
molecular anatomical and behavioral aspects of the disease yet a clear
understanding of the functional aspects of neurotransmission and synaptic
plasticity affected by the loss of MeCP2 remains elusive.
In recent years there has been an effort to shed light in this direction and
to test the hypothesis that RS is a disease of improper synaptic
development/plasticity. Dani et al. in 2005 first characterized cortical activity in
male KO mice [150] using whole cell patch clamp recordings in acute cortical
slices and observed a reduced spontaneous firing rate. This decrease was
apparently not caused by a change in the intrinsic excitability of these cells but
rather by an increase in total inhibitory input over excitatory inputs. Moreover a
small reduction in miniature EPSCs (excitatory postsynaptic currents) was
observed. Interestingly Dani et al. were able to measure a reduction in firing rate
also in samples from 2 weeks old mice, suggesting that what they were
observing was causative of the symptoms and not consequential. Unfortunately
given the complexity of cortical circuitry it was not possible to identify exactly
the signaling pathways that link the lack of MeCP2 to a shift in balance between
excitation and inhibition. Chao et al. using autaptic hippocampal cultures (from
neonatal brain) carried out an in depth electrophysiological analysis of the
reduced excitatory activity and put forward an explanation for the decrease. The
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group reported a reduced number of glutamatergic synapses both in vitro and
in vivo, in the hippocampal CA1 neurons, as demonstrated by a 40% decrease in
VGLUT1 (Vescicular Glutamate Transporter 1) and PSD95 (Post-synaptic density
95) staining [151]. This difference in synapse number was present only in 2
weeks old autaptic MeCP2 KO cultures or in mice younger than 4 weeks of age.
It is difficult to explain why the observed anatomic abnormalities disappear after
two weeks while the symptoms (both electrophysiological and behavioral)
worsen. It is conceivable that MeCP2 plays a role in synapse development, which
is at the basis of what Chao et al. observed, and also has a role in synapse
maintenance, which becomes more important later in age.   MeCP2 deficiency
could affect different brain regions in different ways, so conclusion from
experiments conducted in the cortex might not be generalized to the whole
system.
Another effort to understand the functional aspects of neurotransmission
that are lost in the absence of MeCP2 was made by Asaka et al. and Moretti et
al.. Both groups looked at long-term potentiation (LTP) and depression (LTD) in
the CA1 of the hippocampus either in MeCP2 KO mice or in MeCP2308 mouse
mice. LTP and LTD are a measure of activity dependent synaptic plasticity, which
according to some studies provides the basic mechanism for learning and
memory.  Although memory per se has not be investigated in RS girls, cognitive
abnormalities are definitively present and the study of LTP and LTD might shed
some light on the fundamental synaptic mechanisms affected by RS. A common
finding in the study of Asaka et al. and Moretti et al. is a general reduction of
both LTP and LTD response (this phenotype was observable in fully symptomatic
animals only). In order to look for the origin of the reduction in LTP response,
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both groups examined general basal neurotransmission (in the Shaffer collateral
synapses), and found that while MeCP2308 mice showed an enhancement in
synaptic transmission, the MeCP2 KO mice did not show any change in basal
transmission. Moreover both MeCP2 KO and MeCP2308 mice showed a reduction
in PPF (paired pulse facilitation), which would suggest the presence of a defect
in pre-synaptic function as well. Given that the precise molecular mechanism
underling the LTP and LTD responses are not well understood it is difficult to
draw conclusions about the role of MeCP2 in synaptic plasticity from these
experiments. It remains an open question in fact whether these experiments are
measuring direct effects of the loss of MeCP2 or the result of the compensatory
responses. In support of the former hypothesis is the fact that a similar
reduction in LTP responses has been noticed also in cortical slices from
Huntington’s mouse models [152] l. Interestingly in both in the Huntington’s
mouse ad in the Rett mouse the authors noticed that despite the finding that
LTP, on average, was significantly impaired in mutant compared with wild-type
animals, a small number of mutant slices had an LTP that was comparable to
wild type levels suggesting that the mutation does not disable the LTP
mechanism all together, but rather raised the threshold for inducing it. Reduced
LTP responses are consistent with the overall reduced excitatory cortical activity
seen by Dani et al. but are somewhat in discordance with some of the clinical
observation in patients which often display abnormal electro-encephalograms,
seizures, and prolonged episoded of screaming or crying. In patients motor
cortex stimulation evoked motor action potentials at low threshold and with
abnormally short latencies and prolonged durations, suggesting an enhanced
excitatory activity in the motor cortex in RS subjects under investigation
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[153].Previous studies have speculated that the RS brain may be stalled in an
immature stage of development but if this was the case one would expect
increased synaptic plasticity and LTP and LTD responses.
Neurotrophic factors.
One very important piece of information that would help to correctly
interpret the behavioral and physiological data gathered so far is the systematic
knowledge of all direct targets of MeCP2 regulation. Gene expression profiling
in the mouse knock out model of Mecp2 have been unable to point at any
disregulation of potential target genes in the MeCP2 KO brain [154]. The
heterogeneity of brain tissue might have increased noise levels in these
experiments and masked some potential targets. It is also possible that MeCP2
controls a different sets of genes in different neuronal populations. For this
reason attempts to repeat gene profiling experiments using genetic markers to
isolate specific neuronal subpopulations is underway in several laboratories. At
the same time the advent of a new technology that combines chromatin
immunprecipitations and genome wide hybridization (Chip-CHIP) could
potentially reveal genes that are specifically bound by MeCP2.
So far though only a handful of targets of MeCP2 are known. One of the
first to be isolated is Brain Derived Neurotrophic Factor (BDNF) [155]. BDNF is a
trophic factor that plays an important role in neuronal survival, development
[156, 157] and plasticity [158, 159]. BDNF is highly expressed in neurons and its
transcription is upregulated by membrane depolarization in vitro and by
neuronal activity during kindeling or induction of long term potentiation.
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In primary cortical neuron cultures MeCP2 binds specifically to BDNF promoter
III and functions as a negative regulator of expression. In response to neuronal
activity–dependent calcium influx, MeCP2 becomes phosphorylated and is
released from the BDNF promoter thereby facilitating transcritption [160]. Chen
et al. concluded that MeCP2 plays a key role in the control of neuronal activity-
dependent gene regulation and that the deregulation of this process is a key
cause to the pathology. Contrary to expectations though, MeCP2 KO mice have
lower BDNF levels than normal (70% of wt). Qiang et al. postulated that, given
that BDNF transcription is activity dependent, the observed low excitatory
cortical activity in the KO mice might explain why levels of BDNF are lower
instead of higher. In this circular argument low BDNF levels are both causative
and consequential to the symptoms. In support of the causative hypothesis
Qiang et al. also points at the similarities between the phenotypes of MECP2 KO
mice and BDNF conditional KO mice, namely a decreased brain and neuronal cell
size in the hippocampus which are consistent with an generic atrophic response.
In their study Qiang et al. were able to show that over expression of BDNF in the
frontal cortex can delay the onset of Rett like symptoms and rescue some of the
behavioral and electrophysiological phenotypes described for the MeCP2 KO
mice in Dani et al. Ectopic overexpression of BDNF also rescued the cells size
phenotype (no data are presented on the brain weight phenotype) [161]. So
although the study does not reveal whether BDNF and MeCP2 act through the
same pathway it suggests that some of the symptoms might be an atrophic
response driven by the low levels of BDNF expression, and although BDNF is
only one of the targets of MeCP2 it is the first one shown to be able to modulate
the disease progression. Over expression of such a pleiotrophic factor in the
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brain has been shown to ameliorate symptoms also in a mouse model of
Huntington’s disease [162, 163]. This suggests a possible therapeutic
opportunity by the manipulation of the expression of BDNF or other
neurotrophic factors in cognitive disorders such as RS, schizophrenia,
depression and other autistic spectrum disorders. Some data in support of this
hypothesis are presented in Chapter 3.
Figure 1. The methyl-CpG-binding proteins (MBPs) family. Six mammalian MBPs have been 
characterized so far. Kaiso is an atypical MBP, because it depends on a zinc-finger domain 
(ZF) to recognize methylated DNA and a POZ/BTB domain to repress transcription. MBD1 
uses its methyl-binding domain (MBD) to bind methylated DNA sequences. In addition, 
MBD1 contains three zinc-binding domains (CxxC), one of which binds specifically to 
non-methylated CpG dinucleotides, and a C-terminal transcriptional repression domain 
(TRD). MBD2 possesses an MBD that overlaps with its TRD domain, and a GR repeat at its N 
terminus. MBD3 contains a well-conserved MBD domain that does not recognize methylated 
DNA owing to crucial amino acid changes. MBD4 binds methylated DNA through an MBD 
domain and has a C-terminal glycosylase domain  that is important for is function in DNA 
repair.  MeCP2 is the founding member of the MBD protein family and contains a conserved 
MBD domain and an adjacent TRD domain. 
Klose R.J. et al. Trends in Biochemical Sciences  2006    31: 89-97
Figure 2. MECP2 (methyl-CpG-binding protein 2) gene structure. The positions and 
frequencies of the most common mutations that are associated with Rett syndrome in 
females are indicated. b | The two main protein isoforms, MeCP2A (486 amino acids) 
and MeCP2B (498 amino acids), are produced by alternative splicing of the MECP2 tran-
script and differ in their N-terminal regions, which are encoded by exon 2 of the gene 
in the case of MeCP2A and exon 1 in MeCP2B. MBD, methyl-CpG binding domain; NLS, 
nuclear localization signal; poly(A), polyadenylation; TRD, transcriptional repression 
domain; X, stop codon.
Bienvenu et al. Nature Reviews Genetics (2006) 7, 415–426 
B.The relative expression levels of MeCP2 mRNA are presented for 
peripheral tissues during late embryonic development, and for differ-
ent regions of the brain throughout development. Strong ( +++), 
moderate (++), faint but above background (-), and background ( ) 
reflect the relative intensity of equal exposure time images. ND indi-
cates the structure was not developed at the time of examination, and 
NT indicates the region was not tested. The abbreviations are as fol-
lows: Liv=liver, Int=small intestine, Thy=thymus, Kid=kidney, 
Musc=muscle, Adp=adipose tissue, Cor=neocortex, Pir=piriform 
cortex, Hippo=hippocampus, Stri=striatum, OB=olfactory bulb, 
Thal=thalamus,Amy=amygdala,Pons=pontinenucleus,Cer=cerebellu
m, SC=cervical spinal cord, Ret=retina.
Jung, B. P. J Neurobiol (2003) 55:86-96 
A. MeCP2 mRNA is strongly expressed in the embryonic brain. Anti-
sense in situ hybridization conducted on sagittal sections obtained 
from days E14, E16, and E19 embryos illustrating the mRNA expression 
pattern of MeCP2. Peripheral tissues are as indicated. SC, spinal cord; 
Figure 3
Figure 4. Schematic representation of the spatial and temporal distribution of 
MeCP2 during human and mouse development. The distribution of MeCP2 at 
selected ages during (A) human and (B) mouse CNS development is illustrated. The 
presence of MeCP2 is indicated with red dots. MeCP2 initially appears in the spinal 
cord, specific brainstem nuclei and in the Cajal–Retzius neurons (C-R) of the cere-
bral cortex. Expression is then seen in the midbrain, thalamus, cerebellum and 
deep cortical layers. MeCP2 appears later in the basal ganglia, hypothalamus, hip-
pocampus and latest in the superficial cortical layers.
Shahbazian M. D. et al. Hum. Mol. Genet. 2002 11:115-124;
N. A. Stearns et al.  Neuroscience 146 (2007) 907–921
Figure 5
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Mutations in MECP2 are the cause of Rett syndrome (RTT) in humans, a
neurodevelopmental disorder that affects mainly girls. MeCP2 is a protein that
binds CpG dinucleotides and is thought to act as a global transcriptional
repressor. It is highly expressed in neurons, but not in glia, of the postnatal
brain. The timing of MeCP2 activation correlates with the maturation of the
central nervous system and recent reports suggest that MeCP2 may be involved
in the formation of synaptic contacts and may function in activity-dependent
neuronal gene expression. Deletion or targeted mutation of Mecp2 in mice leads
to a Rett-like phenotype. Selective mutation of Mecp2 in postnatal neurons
leads to a similar although delayed phenotype, suggesting MeCP2 plays a role in
postmitotic neurons. Here we test the hypothesis that the symptoms of RTT are
exclusively caused by a neuronal MeCP2 deficiency by placing Mecp2 expression
under the control of a neuron-specific promoter. Expression of the Mecp2
transgene in postmitotic neurons resulted in symptoms of severe motor
dysfunction. Transgene expression in Mecp2 mutant mice, however, rescued the
RTT phenotype.
Introduction.
Rett-syndrome (RTT), a neurodevelopmental disorder, is a leading cause
of mental retardation in females with an estimated prevalence of 1 in 10,000 to
15,000 female births. RTT patients develop normally until 6-18 month of age
when they start to show symptoms including respiratory irregularities,
progressive loss of motor skills, stereotypic hand movements, seizures, and
features of autism. Examination of the brain reveals profound microencephaly
due, at least in part, to smaller, more densely packed neurons. Other
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abnormalities include a reduction in dendritic arborization (1, 2). In about 80 %
of cases, RTT is associated with mutations in the X-linked MECP2 gene that is
subject to inactivation when located on the inactive X-chromosome (3).
Therefore, heterozygous mutant females are mosaic for MeCP2 deficiency and
show a wide range of phenotypes. Males, however, show a more severe
phenotype usually involving encephalopathy, motor abnormalities and
respiratory dysfunction. They rarely live beyond 2 years (2).
Mecp2 encodes a protein that binds specifically to methylated CpG
dinucleotides and recruits chromatin remodeling complexes that contain the
transcriptional repressor Sin3A and histone deacetylases 1 and 2 (4). In mouse,
the protein localizes to highly methylated pericentromeric heterochromatin (5).
Though MeCP2 is found in most tissues and cell types, highest expression levels
are detected in the brain where it is primarily present in neurons but not in glia
(5-7). The timing of Mecp2 expression correlates with the maturation of the
central nervous system (CNS) (5, 8) and recent reports suggest that MeCP2 may
be involved in the formation of synaptic contacts (9). Although biochemical
evidence suggests that MeCP2 acts as a global silencer, transcriptional profiling
has failed to detect global changes in gene expression (10). A candidate
approach has identified BDNF , a gene involved in neuronal survival,
development, and plasticity, as a target for MeCP2 (11). These findings are
consistent with MeCP2 playing a role in the maintenance and modulation of
neuronal maturity. In particular, MeCP2 may function as a key regulator of
activity-dependent neuronal gene expression.
Complete or partial deletion of Mecp2 in mice leads to a neurological
phenotype that is similar but less severe than human RTT (12, 13).
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Heterozygous females remain healthy into adulthood. In contrast, Mecp2 mutant
males appear normal and healthy at birth but begin to show a phenotype that
resembles the human condition at 3 to 8 weeks of age, and die at 6 to 10 weeks
of age. Mutant brains show a reduction in brain weight and neuronal cell size
but no obvious structural defects or signs of neurodegeneration. Conditional
mutation of Mecp2 in the neural progenitor cells at embryonic day 12 results in
a phenotype identical to that of the null mutation (12). Mutation of Mecp2 in the
postnatal neurons of restricted regions in the brain leads to a similar although
delayed neuronal phenotype, suggesting MeCP2 plays a role in postmitotic
neurons (12). Here we test the hypothesis that the phenotype is exclusively
caused by a neuronal MeCP2 deficiency by placing Mecp2 expression under the
control of a neuron-specific promoter. Overexpression of the Mecp2 transgene
in postmitotic neurons proved to be detrimental and lead to symptoms of severe
motor dysfunction. Transgene expression in Mecp2 mutant mice, however,
resulted in a rescue of the RTT phenotype.
Materials and Methods
Gene targeting construct.
To introduce the Mecp2 coding sequence as an in-frame fusion into exon
1 of the tau locus we first cloned a 3.8 Kb KpnI/EcoRI fragment from pHV, which
contains 14 Kb of tau genomic sequence (kindly provided by K. Tucker) into
pBluescript (Stratagene) generating  pTau-KR with a unique NcoI cloning site.
Next we eliminated a unique SpeI site in the polylinker of pTau-KR by cutting
the vector with SpeI, treating it with the DNA polymerase I Klenow fragment
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(New England Biolabs) and religating it. We created pTau-KR-linker by
introducing suitable restriction sites to allow the in-frame fusion. We inserted
an adapter that destroyed the NcoI cloning site while introducing a new NcoI site
that was shifted by 2 bp, plus a SpeI and an EcoRV site. The primers used were
TAUadapt-F (5'-TTT GGT CAT GAT GCC ATG GAC TAG TCG ATA TCT CAT GAG
ATT A-3') and TAU-link-R (5'-TAA TCT CAT GAG ATA TCG ACT AGT CCA TGG
CAT CAT GAC CAA A-3'). The 1455 nucleotide-long coding sequence of Mecp2
was amplified by PCR from IMAGE clone 1395411 (AI181668) and confirmed by
sequencing. The PCR primers introduced a modified Kozak sequence including
an NcoI site (ATTCCATGG was changed to CCACCATGG) and restriction sites
t h a t  f a c i l i t a t e d  c l o n i n g .  P r i m e r  R I - M e C P 2 - F  ( 5 ' -
cggaattccgccaccatggtagctgggatgttaggg-3') added an EcoRI site 5' of the
sequence, and primer Xba-MeCP2-R (5'-gctctagagctcagctaactctctcggtcacg-3')
added an XbaI site to the 3' end. To provide the construct with an SV40 late
polyadenylation signal (SV40pA) we next cloned the EcoRI/XbaI MeCP2 fragment
into the EcoRI/SpeI digested vector pZ12-I-PL2 (Ariad). MeCP2-SV40pA was
released as an NcoI/SpeI fragment and cloned into pTAU-KR-linker creating
pTAU-MeCP2pA. A neoR-resistance selectable marker from pPGKNR was isolated
using EcoRI and SalI and overhangs were filled in using Klenow. This blunt-
ended fragment was cloned into the unique EcoRV site of pTAU-MeCP2pA. The
targeting vector pTAU-MeCP2pAneo was confirmed by sequencing.
Generation of mice.
The targeting vector was linearized with SacII and electroporated into
V6.5 (129 x C57BL/6) F1 embryonic stem (ES) cell lines. We picked 96
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neomycin-resistant clones of which 63 were analyzed by Southern blots as
described (14).The 5' external probe consisted of a 528bp PCR fragment
amplified from pHV and was located 1.5 Kb upstream of the NcoI insertion site
in exon 1. The primers were Tau5'-F (5'-GAG CTG CTG CCA TCT TCA C-3') and
Tau5'-R (5'-TTT GAT GTG TGC CCT ACA GAA-3'). The 3' external probe
consisted of a 600 bp BamHI/EcoRI genomic fragment (15) that was located 6.1
Kb downstream of the insertion site. An internal probe was used to test for
additional non-homologous insertions and consisted of a 200 bp PstI fragment
from the neoR ORF (15). Eleven clones were targeted correctly which
corresponds to a targeting efficiency of 17%. Two clones were used to generate
chimeras by injection into (DBA/2 x C57BL/6) F1 blastocysts as described (16).
Chimeras were mated to C57BL/6 females and offspring were analyzed for
germline transmission. The heterozygous knock-in strain (Tau-Mecp2 ki/+) was
maintained on a mixed background that was predominantly C57BL/6 but also
contained some 129 contributed by the original ES cells used for targeting. To
obtain rescued males, Tau-Mecp2 ki/+ heterozygous males were mated to
heterozygous Mecp1lox/+ females (12) that had been backcrossed to C57BL/6.
After germline transmission was confirmed animals were routinely genotyped by
PCR. For the tau locus the primer set Tau138 (5'-CTG GCA GAT CTT CCC GTC
TA-3'), Tau1078 (5’-TGC CTG ACA GAG TCC AGA TG-3’) and Neo1323 (5'-AGG
GGA TCC GTC CTG TAA GT-3') gave a 941 bp band for the wild-type allele and
a 796 bp band for the ki allele. The Mecp2 allele was determined using primers
Nsi-5 (5’-CAC CAC AGA AGT ACT ATG ATC-3’), 2lox-3 (5’-CTA GGT AAG AGC
TCT TGT TGA-3’) and Nsi-3 (5’-ATG CTG ACA AGC TTT CTT CTA-3’), which
generated a 180 bp wild-type band and 300 bp band for the 1lox allele.
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Immunoblot analysis.
Organs were routinely harvested and snap frozen in liquid N2. Tissues
were homogenized with a Polytron homogenizer (Biospec Products Inc.) in a
lysis buffer containing 125 mM Tris, 1% SDS (pH 6.8) supplemented with a
proteinase inhibitor cocktail (Roche). Protein concentrations were determined
with a BCA protein assay kit (Pierce, Rockford, IL).  Sample buffer containing
bromophenol blue was added to final concentrations of 12.5% glycerol and
0.25% ß-mercaptoethanol. 40?g of protein (unless indicated otherwise) was
loaded on 7.5% Tris-HCL acrylamide gels (Ready Gels, BIO-RAD), probed with an
anti-MeCP2 rabbit polyclonal antibody (Upstate Biotech) or an anti-GAPDH
rabbit polyclonal (Abcam) and visualized using the Amersham ECL system.
Immunohistochemistry.
Brains were harvested from 8 weeks old animals, weighed, immersion-
fixed for 20 h in 10%  phosphate buffered formalin  and cryoprotected for 24 to
36 h in 30% sucrose and embedded in OCT. A series of 15 ?m sagittal sections
were slide mounted and stored at -20˚C. For immunohistochemistry slides were
blocked in 5% normal goat serum and incubated with rabbit antibody raised
against the C-terminal peptide of MeCP2 (11) at a dilution of 1:500 and a
mouse anti neuron specific nuclear protein (NeuN, Chemicon) at a dilution of
1:200. The MeCP2 antibody was detected with a FITC conjugated goat anti-
rabbit IgG and the NeuN antibody with a Rhodamine conjugated donkey anti-
mouse IgG (both from  Jackson Imunoresearch), both at a dilution of 1:500.
Sections were finally rinsed in PBS/DAPI (1:10000) and mounted in Vectashield
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(Vector laboratories). Images were taken with Leica fluorescence microscope
under 20x magnification.
RNA samples and RNase Protection assay.
Embryo heads and adult brains were harvested, snap frozen in liquid N2
and subsequently extracted with RNA-Bee (TEL-Test, INC.). Embryos were
isolated from Tau-Mecp2 ki/+ females mated with Tau-Mecp2 ki/+ males.
Embryos of the correct genotype were identified by PCR genotyping using DNA
extracted from embryos (10.5 to 15.5 d.p.c.), yolk sac (9.75 d.p.c.) or tail tips.
For the RNase protection assay the probe template was generated by PCR from
genomic DNA obtained from a transgenic mouse with primers TauExon1-27F
(5 ' -GCCAGGAGTTTGACACAATG-3 ' )  and  MeCP2-282R  (5 ' -
CATACATAGGTCCCCGGTCA-3'). The PCR product was cloned into the vector
pCR2.1-TOPO (TOPO TA Cloning Kit, Invitrogen) and subcloned as a PstI
Fragment into the transcription vector pSP72 (Promega). In vitro transcription
was carried out with the Maxiscript T7 Kit (Ambion,). UTP?P32 (3,000 Ci/mmol,
10 mCi/ml,  Amersham Pharmacia) was diluted 1:10 with unlabeled nucleotide
and the probes were gel-purified. 2000 cpm of probe and 10 ?g of total RNA
was used in the assay according to the manufacturer's specification (Ambion
RPA III kit). The samples were resolved on a 6% acrylamide (1:30 bisacrylamide)
and quantified by phosphor imaging.
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Spontaneous activity measurements.
Motor activity was measured using an infrared beam activated
movement-monitoring chamber (Opto-Varimax-Mini-A, Columbus
Instruments). For each experiment, a mouse was placed in the chamber at least
3 hours before recordings started. Movement was monitored during the normal
12 h dark cycle (7 pm to 7 am).
Results
Expression of MeCP2 from the tau locus.
In order to express MeCP2 specifically in post-mitotic neurons we
designed a targeting construct that places Mecp2 expression under the control
of the promoter of the microtubule-binding-protein, Tau. Tau protein is
strongly expressed in neurons (17) and the endogenous tau locus has been
used previously to drive neuron-specific expression of EGFP (15). Homozygous
animals mutant for tau have been shown to be phenotypically indistinguishable
from wild-type littermates (18). A cDNA containing the Mecp2 coding sequence
including a modified Kozak sequence (19) was placed into exon 1 of the tau
gene in-frame with the endogenous initiation codon thereby creating a fusion
protein that contains the first 31 amino acids of Tau (Tau-MeCP2, Fig. 1A). The
targeting construct was introduced into V6.5 embryonic stem cells by
electroporation and 63 neomycin-resistant clones were analyzed. Eleven clones
were targeted correctly and two of these (Fig. 1B) were used to generate germ
line-transmitting chimeras.
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To examine and compare the expression pattern of Tau-MeCP2 and
endogenous MeCP2, we determined their protein levels in various adult mouse
tissues by immunoblot analysis (Figure 2A, B). We found that Tau-MeCP2
expression in the brain was 2-4-fold higher than endogenous MeCP2 (Fig. 2A,
lanes 4 to 9). Endogenous MeCP2 was expressed highly in lung and spleen, and
moderately in kidney and heart and liver (Fig 2B, wt). Tau-MeCP2 protein
expression was high in lung and kidney, and was low in heart (Fig. 2B, R). Very
low expression in liver and spleen was detectable after long exposure times.
MeCP2 localizes to highly methylated centromeric heterochromatin (20),
and immunohistochemical analysis revealed the typical punctate nuclear MeCP2
staining pattern in wild-type brains (Fig. 2C). This pattern was not detectable in
Mecp2 mutant animals. Instead a faint diffuse nuclear staining was observed
which probably arose from the detection of the truncated MeCP2 protein (Fig.
2G) (12). The deletion of exon 3 encompasses most of the methyl-CpG-binding
domain (MBD) but the C-terminal epitope including the nuclear localization
sequence (NLS) remains largely intact (12). We found that in Mecp2 mutant mice
heterozygous for the Tau-Mecp2 transgene (rescued animals) MeCP2
distribution was indistinguishable from wild-type MeCP2 (Fig. 2K) suggesting
correct localization of the fusion protein.  This was to be expected, because the
MBD and the NLS have both been shown to be necessary and possibly sufficient
for the specific localization of MeCP2 (20). The axonal localization signal of Tau
is located in the 3' untranslated region (UTR) and therefore not part of the Tau-
MeCP2 mRNA (21). In addition we found that all MeCP2-positive cells were
double labeled with an antibody against the neuron-specific marker protein
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NeuN (22) (Fig.2E, M, Q) indicating that endogenous MeCP2 as well as Tau-
MeCP2 were detectable only in neuronal cells (Fig. 2F, N, R).
Timing of Tau-MeCP2 expression.
In order to quantify the relative expression of Mecp2 and Tau-Mecp2
during embryonic development we carried out an RNase protection assay (RPA)
on embryos harvested between 9.75 and 15.5 days past coitum (d.p.c.). The
probe (RPA) was designed to span the Tau-Mecp2 junction including 82 bp of
tau exon 1 and 164 bp of the Mecp2 cDNA. This allowed the detection of the
Tau-Mecp2 RNA as well as the endogenous Mecp2 and tau transcripts (Fig. 3A).
Mecp2 RNA was detectable as early as 9.75 d.p.c. with levels steadily increasing
until they reached adult levels at 15.5 d.p.c (Fig. 3B, compare lane 5 with lanes 6
and 9). Tau-Mecp2 expression followed closely that of endogenous tau with
RNA being present starting at 10.5 d.p.c. and, like Mecp2, reaching maximum
expression levels at 15.5 d.p.c (Fig. 3B, compare lane 5 with lanes 6 and 9). The
timing of Tau-Mecp2 expression therefore appeared to closely mimic that of
Mecp2.
Quantification of expression levels revealed that in 15.5 d.p.c. embryonic
heads as well as in adult brains the amount of Mecp2 RNA appeared to be
similar to Tau-Mecp2 RNA. On the protein level, however, Tau-MeCP2 was 2-4
times more abundant (Fig. 2A) suggesting a difference in either translation
efficiency of the transcripts or protein stability.
Overexpression of MeCP2 is detrimental.
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Wild-type animals heterozygous for the transgene were fertile and
healthy with no obvious phenotypic abnormalities. In contrast, wild-type as well
as Mecp2 mutant animals homozygous for the transgene suffered from
profound motor dysfunction including side-to-side swaying, tremors and gait
ataxia.  There was no reduction in brain weight in animals at 2 to 4 month of
age (data not shown). Animals were of normal weight at birth, but by weaning
age pups were severely runted and up to 60% smaller than wild-type littermates
(Fig. 4B). The condition improved when animals were fostered in small groups,
indicating that the failure to thrive was largely due to their inability to compete
with littermates for food. Once the animals reached weaning age the phenotype
appeared to be stable, but they remained small and do not mate.  By 9 month
ataxia and tremors appeared to have intensified.  The animals were emaciated,
had a disheveled look, and developed additional problems such as cataracts and
lesions. The lesions were probably caused by excessive stereotypic scratching.
However, no premature death was observed. Preliminary data suggest that
Mecp2-mutant animals homozygous for the transgene were slightly less
affected compared to Mecp2 wild-type animals homozygous for the transgene
as judged by weight and appearance (data not shown). The phenotype was
specific and not due to the lack of Tau protein because animals homozygous for
other transgenes targeted to exon 1 of the tau locus were phenotypically normal
(15 and unpublished data).
Immunohistochemical analysis of brain sections revealed a punctate
MeCP2 staining pattern (Fig. 2M) suggesting that the level of Tau-MeCP2
overexpression had no effect on Tau-MeCP2 localization in adult mice. Previous
reports detected diffuse nuclear MeCP2 staining at 10 d.p.c. which became
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increasingly punctate through 16.5 d.p.c. (5). Our results suggest that MeCP2
dosage is critical and that overexpression of MeCP2 4- to 6 -fold above wild-
type level is detrimental to the health of the animal.
Expression of MeCP2 in postmitotic neurons rescues the RTT phenotype.
MeCP2 mutant mice die on average around 10 weeks of age(12). In
contrast, mutant animals heterozygous for the transgene were healthy and
fertile and in various crosses passed on all alleles at the expected Mendelian
ratios (data not shown). They were phenotypically indistinguishable from their
wild-type littermates and displayed no RTT-like symptoms (Fig. 4A). A distinct
feature of Mecp2 mutant animals are weight abnormalities, and in agreement
with previous reports (13) Mecp2 mutant animals were severely underweight
from four to five weeks  (Fig4C). In contrast, the weight of rescued animals was
indistinguishable from that of wild-type littermates throughout postnatal
development (Fig. 4C).
Human RTT syndrome, as well as the Mecp2 mutant mouse phenotype,
are characterized by a decrease in head growth and neuronal cell size as well as
increased cell packing density throughout the brain (12, 23-25). As published
previously we found a 14 - 18 % reduction in brain weight in 8 to 13 week old
Mecp2 mutant animals. In contrast, rescued animals showed no difference in
brain weight compared to wild-type littermates, even when brains were
harvested as late as 5 months of age (Fig.4D). Hypoactivity is another
characteristic of Mecp2 mutant mice (12, 13, 26). We tested exploratory
response as well as total nocturnal activity by placing animals in cages equipped
with an infrared beam movement detector. The age of the mice tested ranged
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from 4 to 6.5 months, long after the onset of RTT symptoms in Mecp2 mutant
mice and in all cases after Mecp2 mutant littermates had died. In both
behavioral tests rescued animals were indistinguishable from wild-type
littermates (Fig. 4E).
In summary, our data indicate that rescued animals do not display any of
the common RTT phenotypes that have been described for Mecp2 mutant
animals. Therefore expression of Mecp2 in postmitotic neurons is sufficient to
alleviate the RTT phenotype, even at slightly elevated protein levels.
Discussion.
Mutation of the methyl-binding protein MeCP2 leads to RTT in humans,
and increasing evidence suggests that this disorder is primarily caused by a
defect in neuronal maintenance and maturation. In a mouse model, loss of
MeCP2 expression leads to a RTT-like phenotype including tremors, heavy
breathing, hypoactivity and smaller brain size associated with smaller, more
densely packed neurons. After the onset of symptoms at 4 to 6 weeks of age
and progressive physical deterioration, the animals typically die around 10-12
weeks of age (12, 13). Deletion of Mecp2 exon 3 encoding most of the methyl-
binding domain in neural progenitor cells produces a phenotype that is
indistinguishable from the germline mutation. In contrast, loss of MeCP2
function in postmitotic neurons of the postnatal brain led to a delayed onset of
symptoms by up to 3 months (12). MeCP2 is primarily expressed in mature
neuronal populations (5-7) with an expression pattern that follows the
maturation of the CNS (5). Recent studies suggest that MeCP2 may be important
for the maintenance and modulation of synapses (9). In addition, neurons of
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RTT individuals appear to show a reduction in dendritic complexity (27). Also,
recent experiments in Xenopus revealed a specific function of MeCP2 in early
neural development (28).
Here we provide functional evidence for the requirement of MeCP2 in
postmitotic neurons by placing the Mecp2 cDNA under the control of the
endogenous promoter of the microtubule-binding-protein, Tau. By introducing
the cDNA into exon 1 of the tau gene in-frame with the endogenous start codon
we created a fusion protein that contained the first 31 amino acids of Tau (Tau-
MeCP2). Tau-MeCP2 was expressed at a level 2-4-fold higher than endogenous
MeCP2, and the onset of expression correlated closely with endogenous tau
expression being first detectable at 10.5 d.p.c. In agreement with previous
reports, endogenous M e c p 2  RNA was detectable at 9.75 d.p.c.
Immunohistochemical analysis of brain sections revealed that Tau-MeCP2
localized like endogenous MeCP2 to heterochromatic foci of postmitotic
neurons in adult mice.
One copy of the Tau-Mecp2 transgene led to the complete rescue of all
assessed phenotypes in Mecp2 mutant animals. They had a normal lifespan and
showed normal physical development as judged by weight. The rescued animals
had normal brain weight and showed no signs of hypoactivity, tremors or any
other physical symptoms typically associated with RTT, even at an advanced age
of 6 month or more. We therefore conclude that expression of MeCP2 in
postmitotic neurons is sufficient to alleviate the phenotype in MeCP2 mutant
mice. Our data strongly suggest that the RTT phenotype is caused by lack of
MeCP2 in the brain. Nevertheless, we cannot fully exclude a contribution of
MeCP2 in some peripheral tissues, because the physiological basis of some
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symptoms in Rett patients as well as in Mecp2 mutant animals still remains to
be determined.
It has been reported previously that there is no obvious correlation
between MeCP2 protein and RNA levels in adult tissues, suggesting that Mecp2
translation may be postranscriptionally regulated (5). The endogenous Mecp2
sequence contains a 182 bp 5' UTR and a highly conserved 8.5 Kb 3' UTR with
alternative polyadenylation (pA) signals. Depending on which pA signal is used,
either a 1.9 Kb or a 10 kb transcript is produced. In the brain the 10 Kb
transcript is the predominant one (29). In our experiments, the Tau-Mecp2
construct did not include either of the untranslated regions. Since both the short
and the long transcript have similar half-lives (29) it is possible that the 3'UTR
contains regulatory elements important for translation efficiency. In fact, the
Mecp2 3'UTR has recently been predicted to contain potential target sequences
for microRNAs (miRNAs), which confer posttranslational repression (30).
Moderate overexpression of MeCP2 in wild-type mice heterozygous for
Tau-Mecp2 had no adverse effect. In contrast, homozygosity for the transgene
led to severe motor dysfunction in a wild-type as well as a Mecp2 mutant
background. The result was an impaired ability to compete with littermates for
food, leaving the pups severely runted. Symptoms included tremors, gait ataxia
and side-to side swaying. These observations suggest that neurons can tolerate
a 2 to 3-fold higher level of MeCP2 expression but that higher expression levels
result in obvious detrimental consequences. Interestingly, Mecp2 mutant
animals homogzygous for the transgene showed a slightly less severe
phenotype, which emphasizes the importance of MeCP2 dosage.
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We found that MeCP2 expression was dispensable through early
embryonic development. In agreement with this, previous studies described that
MeCP2 expression was undetectable before 9.5 d.p.c on the RNA or protein level
indicating that it plays no essential role in early embryonic development (5, 31).
Moreover, we find that MeCP2 is not necessary for neurogenesis, despite the
fact that MeCP2 appears to be expressed in some neuronal precursor cells of
the rodent brain (32). The delayed phenotype of the conditional mutant
observed after postnatal loss of MeCP2 function in postmitotic neurons may be
attributable to the fact that the expression of CamKII-driven Cre recombinase
used in this experiment is limited to certain parts of the postnatal brain
including the forebrain, hippocampus and brainstem. It is only marginally active
in the cerebellum, a region where Mecp2 mRNA is highly expressed (32). In
contrast, loss of MeCP2 function in neural progenitor cells affects essentially all
neurons. It is also possible that the abatement of the phenotype of CamKII-Cre
mutants is due to the presence of MeCP2 in neurons during prenatal
development or the lack of Cre expression in a crucial cell type.
Our results are consistent with MeCP2 playing no essential role in the
early stages of brain development. It is possible in fact, that neurons are
functionally normal in the young postnatal patient, and that neural dysfunction
becomes manifest only later due to prolonged MeCP2 deficiency. If correct,
therapeutic strategies could be aimed at preventing postnatal dysfunctions from
developing in MECP2 mutant neurons.
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Figure Legends.
Figure 1. Targeting the Mecp2 cDNA to the tau locus. A. Targeting strategy to
insert the Mecp2 cDNA and the neomycin resistance marker (NEOR) into exon 1
of the tau locus. The upstream and downstream targeting arms are shown in
light and dark grey, respectively. The locations of 5' and 3' external probes used
for Southern blot analysis are indicated.  B. Southern blot analysis of targeted ES
cell clones (ki/+) after digestion with BamHI (left panel) and KpnI (right panel).
When hybridized with the 5' external probe, wild-type clones display a 9 Kb
band. The correct targeting event results in a band-shift to 4.75 Kb for the
targeted allele. Hybridization with the 3' external probe results in a 8.8 Kb wild-
type band and a 12.5 Kb band for the targeted allele.
Figure 2. Expression of Mecp2 from the tau locus. A. Immunoblot analysis of
protein prepared from whole brain samples. As controls, 40 ?g of protein were
loaded from wild-type and MeCP2 mutant (MeCP2 KO) animals, and MeCP2
mutant animals heterozygous for the Tau-MeCP2 transgene (Rescue). The
protein extract from a MeCP2 wild-type animal heterozygous for the transgene
(Tau-MeCP2 ki/+) was loaded as serial dilutions as indicated. The Tau-MeCP2
fusion protein contains 31 amino acids of the Tau protein which results in a
band shift. B. Endogenous MeCP2 (wild-type animal, wt) is highly expressed in
the lung and spleen, and less in the liver, kidney and heart. Tau-MeCP2
expression (rescued animal, R) is high in lung and kidney. Low level expression
is also detectable in the heart. In the liver and spleen Tau-MeCP2 is detectable
only after long exposure times. C-R. Tau-MeCP2 expression is neuron-specific
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in the brain and localizes to heterochromatic foci. Double labeled immuno-
fluorescence of MeCP2 (green) and neuron-specific nuclear protein (NeuN, red)
from wild-type (C-F), MeCP2 KO (G-J), rescued (K-N) and Tau-MeCP2
homozygous (Tau-MeCP2 ki/ki, O-R) hippocampi of adult animals. Punctate
MeCP2 staining is detectable in wild-type animals (C) as well as animals carrying
the Tau-MeCP2 transgene (K, O). Inserts in panels C, G, K, O show enlargements
of a small number of cells to illustrate MeCP2 staining. Endogenous MeCP2 as
well as Tau-MeCP2 expression overlaps with NeuN immunoreactivity (F, N, R).
Only weak diffuse MeCP2 staining is present in MeCP2 null cells (G). Nuclear
DAPI stain is shown in blue (E, I, M, Q).
Figure 3. Timing of Tau-Mecp2 expression. A. Probe design for the RNase
protection assay. The probe overlaps the Tau-Mecp2 junction of the transgene
and consists of 82 bp of tau sequence and 164 bp of Mecp2 cDNA sequence (26
bp of exon 2 and 138 bp of exon 3). B. RNase protection assay. RNA was
extracted from embryos (9.75 d.p.c) and embryonic heads (10.5 to 15.5 d.p.c.)
of Mecp2 wild-type animals heterozygous for the Tau-Mecp2 transgene (lanes 1
- 5), or from brains of adult control animals (lanes 6 - 9). Lane 10 shows the no
sample control, and lane 11 is 15% loading of the no RNase control. Wild-type
Mecp2 RNA is detectable as two bands that probably represent different splice
products (lanes 1 - 6 and 9). No Mecp2 signal is detectable in animals carrying
the mutant Mecp2 allele that lacks exon 3 (lanes 7 and 8). The ratio of Tau-
Mecp2 RNA expression to endogenous Mecp2 RNA as quantitated by
phosphorimaging is given below the gel.
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Figure 4. Expression of MeCP2 in postmitotic neurons rescues the RTT
phenotype, but overexpression of MeCP2 is detrimental. A. Rescued animals
are indistinguishable from their wild-type litter mates. Animals are shown at 8
weeks of age. B. Mecp2 wild-type animals heterozygous for Tau-Mecp2 (Tau-
Mecp2 ki/+) show normal physical development. Mecp2 overexpressing animals
(Tau-Mecp2 ki/ki) have a normal birth weight but progressively lose weight so
that animals are up to 60% smaller than wild-type littermates at weaning age. C.
Neuronal expression of MeCP2 rescues the weight-loss phenotype. Mecp2 null
animals start to lose weight at about 5 weeks of age. The weight of rescued as
well as Tau-Mecp2 ki/+ animals is comparable to that of wild-type littermates.
D. Rescued animals have a brain weight comparable to wild-type littermates. In
contrast, Mecp2 mutant animals show a 15 - 18 % reduction in brain weight. E.
Spontaneous activity of rescued animals is comparable with the activity of wild-
type littermates as measured by an infrared beam activated movement detector.
Fig. 1.Targeting the MeCP2 cDNA to the tau locus. (A) Targeting strategy to insert the 
Mecp2 cDNA and the neomycin resistance marker (NEOR) into exon 1 of the tau 
locus. The upstream and downstream targeting arms are shown in light and dark 
gray, respectively. The locations of 5  and 3  external probes used for Southern blot 
analysis are indicated. (B) Southern blot analysis of targeted embryonic stem cell 
clones (ki  ) after digestion with BamHI (Left) and KpnI (Right). When hybridized with 
the 5  externalprobe, wild-type clones display a 9-kb band. The correct targeting 
event results in a band-shift to 4.75 kb for the targeted allele. Hybridization with the 
3  external probe results in a 8.8-kb wild-type band and a 12.5-kb band for the 
targeted allele.
Fig. 2. Expression of MeCP2 from the tau locus. (A) Immunoblot analysis ofprotein prepared 
from whole brain samples. As controls, 40  g of proteinwere loaded from wild-type and Mecp2 
mutant (Mecp2 KO) animals, and Mecp2 mutant animals heterozygous for the Tau-Mecp2 
transgene(Rescue). The protein extract from a Mecp2 wild-type animal heterozygous for the 
transgene (Tau-Mecp2 ki  ) was loaded as serial dilutions as indicated. The Tau-MeCP2 fusion-
protein contains 31 aa of the Tau protein, which results in a band shift. (B) Endogenous MeCP2 
(wild-type animal, wt) is highly expressed in the lung and spleen,and less in the liver, kidney, 
and heart. Tau-MeCP2 expression (rescued animal, R) is high in lung and kidney. Low-level ex-
pression is also detectable in the heart. In the liver and spleen Tau-MeCP2 is detectable only 
after long exposure times. (C–R) Tau-MeCP2 expression is neuron-specific in the brain and 
localizes to heterochromatic foci. Double labeled immuno-fluorescence of MeCP2 (green) and 
neuron-specific nuclear protein (NeuN, red) from wild-type (C–F), Mecp2 KO (G–J), rescued 
(K–N) and Tau-Mecp2 homozygous (Tau-Mecp2 ki ki, O–R) hippocampi of adult animals are 
shown. Punctate MeCP2 staining is detectable in wild-type animals (C) as well as animals carry-
ing the Tau-Mecp2 transgene (K and O). Insets in C, G, K, and O show enlargements of a small 
number of cells to illustrate MeCP2 staining. Endogenous MeCP2 as well as Tau-MeCP2 expres-
sion overlaps with NeuN immunoreactivity (F, N, and R). Only weak diffuse MeCP2 staining is 
present in Mecp2 null cells (G). Nuclear 4 ,6-diamidino-2-phenylindole (DAPI) stain is shown in 
blue (E, I, M, and Q).
Fig.3. Timing of Tau-Mecp2 expression. (A) Probe design for the RNase
protection assay. The probe overlaps the Tau-Mecp2 junction of the transgene
and consists of 82 bp of Tau sequence and 164 bp of Mecp2 cDNA sequence (26
bp of exon 2 and 138 bp of exon 3). (B) RNase protection assay. RNA was
extracted from embryos (9.75 dpc) and embryonic heads (10.5–15.5 dpc) of
Mecp2 wild-type animals heterozygous for the Tau-Mecp2 transgene (lanes
1–5), or from brains of adult control animals (lanes 6–9). Lane 10 shows the no
sample control, and lane 11 is 15% loading of the no RNase control. Wild-type
Mecp2RNAis detectable as two bands that probably represent different splice
products (lanes 1–6 and 9). No Mecp2 signal is detectable in animals carrying
the mutant Mecp2 allele that lacks exon 3 (lanes 7 and 8). The ratio of
Tau-Mecp2 RNA expression to endogenous Mecp2 RNA as quantitated by
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In humans mutations in the X-linked MECP2 gene, are the cause of Rett
syndrome (RTT), a neurodevelopmental disorder that affects mainly girls. MeCP2
binds to methylated CpGs and is thought to act as a transcriptional repressor. In
male mice, deletion or targeted mutation of Mecp2 leads to lethality and causes
a neuronal phenotype. Selective mutation of Mecp2 in postnatal neurons results
in a similar although delayed phenotype, suggesting that the symptoms are
caused by MeCP2 deficiency in postmitotic neurons. In agreement with this idea,
expression of a Mecp2 transgene in postmitotic neurons of Mecp2 null mutant
mice resulted in the phenotypical rescue of the symptoms. To assess whether
postnatal activation of MeCP2 in mutant animals could also affect the
progression of the disorder, we constructed a conditionally active Mecp2 "rescue
transgene" which was activated between P0 and P30.  The Mecp2 transgene was
under the control of the CAGGS promoter and was activated using brain specific
Cre-mediated recombination. Our results indicate that post-natal, neuron-
specific activation of MeCP2 as late as 2 to 4 weeks of age significantly
prolonged the lifespan of mutant animals and delayed the onset of neurologic
symptoms.
Introduction.
Rett syndrome (RTT) is an X-linked neurological disorder that
predominantly affects girls (1). First signs of illness include deceleration of head
growth between 2-4 months of age. Affected individuals usually develop full-
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blown symptoms between the ages of 1 and 4 years. The disorder is
characterized by social withdrawal, loss of motor skills and gait ataxia. Many
affected individuals develop stereotypic hand movement and autonomic
dysfunctions such as irregular respiration. All RTT subjects have severe mental
retardation.
Mutations in the X-linked MECP2 gene (methyl-CpG binding protein 2)
account for nearly 80% of RTT cases (2-5). To study the RTT etiology, we and
others established mouse models by engineering Mecp2 gene deletions (6-8).
Conditional mutations have shown that although MeCP2 is also expressed
outside the nervous system, deficiency in neurons is responsible for the
phenotype (7). Electrophysiological analyses demonstrated that MeCP2
deficiency shifts the balance between excitation and inhibition in cortical
neurons (9) and, more recently, MeCP2 has been implicated in regulating RNA
splicing (10). Male mutant mice develop normally until 4-5 weeks of age, when
RTT-like symptoms become manifest including reduced brain weight, decreased
CA2 neuron size, hindlimb clasping, and impaired locomotor function (6, 7). A
recent study showed that postnatal loss of MeCP2 in the forebrain is sufficient
to cause many of the behavioral aspects of RTT in mice (11).
Given the strong biochemical evidence that MeCP2 binds methylated
CpGs and functions in establishing or maintaining a repressive chromatin state
by recruiting histone deacetylases (12-14) and H3 K9 methylating enzymes (15)
it is surprising that only few differences in gene expression were observed
between wt and mutant (16-20). Among the identified targets of MeCP2 are
glucocorticoid regulated genes (19), Hairy 2 (21), and Bdnf. Bdnf (Brain-derived-
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neurotrophic-factor), the first identified target gene, is repressed in resting
neurons by binding of MeCP2 to the neuronal specific promoter region. Resting
neurons from Mecp2 null animals have slightly higher BDNF expression (22-24)
whereas calcium influx triggers MeCP2 phosphorylation leading to Bdnf
activation (25). Recent in vivo data suggested a functional interaction between
the two genes since over-expression of BDNF was shown to extend the lifespan,
to partially rescue locomotor defects, and to reverse the electrophysiological
deficits of MeCP2 deficient animals (24, 26). MeCP2 has also been implicated in
the regulation of imprinted genes such as Ube3a (27), Gabrb3 (28) and Dlx5
(29), although some of these claims have been challenged (30). Thus, in spite of
the great insights derived from those studies it remains unclear whether Rett
syndrome is the result of misregulation of few key genes, such as Bdnf, or
whether it is caused by misregulation of multiple genes each with an
incremental contribution to the phenotype.
Because overt symptoms become manifest only at 1-2 years of age in
RTT females and at 4-5 weeks of age in male Mecp2 mutant mice, it would be
important to know whether the behavioral and physiological symptoms are due
to abnormal brain development or to neuronal dysfunction caused by MeCP2
deficiency in mature neurons. If MeCP2 plays an ongoing critical role in mature
CNS neurons and only prolonged deficiency leads to neuronal dysfunctions, it
may be possible to restore these functions by reactivating MeCP2 or by affecting
expression of other genes in adult neurons.  Indeed, previous results have
demonstrated that a Tau promoter driven reactivation of a Mecp2 transgene in
postmitotic neurons rescued the MeCP2 deficient phenotype in mice (31). These
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experiments did not address the possibility that activation of MeCP2 at later
ages could affect the course of the disorder. Here we use Cre-mediated
recombination in Mecp2 -/y mice to show that activation of MeCP2 as late as 2-
4 weeks of age can delay lethality and the onset of symptoms.
Results.
Generation of the CAGGS Lox-Stop-Lox Mecp2 transgene.
To investigate whether the phenotype in MeCP2 deficient mice could be
affected by post-natal, brain-specific reactivation of MeCP2, we engineered a
conditional rescue transgene. MeCP2 is present in two isoforms: e1 and e2 (32-
34). These isoforms have a slightly different N-terminal region and are
expressed at different levels but have been demonstrated to be functionally
equivalent in mice as brain expression of the e2 isoform alone rescued the
phenotype of Mecp2 -/y mice (31). We used the mouse Mecp2e2 cDNA placed
downstream of a Stop cassette containing a neo resistance gene and three
polyadenylation signals (Fig. 1A). The synthetic CAGGS promoter, a hybrid
promoter-enhancer containing the b-actin enhancer and the CMV early
promoter (35), was placed upstream of the Stop cassette. Because the Stop
cassette was flanked by LoxP sites (36), Cre mediated recombination would
result in expression of MeCP2e2 from the CAGGS promoter. C10 ES cells were
used to target the transgene to the modified Col1a1 locus by frt/Flpe
recombinase-mediated site-specific integration (37) and the targeted ES cells
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were injected into blastocysts to generate CAGGS LoxP-Stop-LoxP (LSL) Mecp2
mice.
To test whether the LSL element repressed the transgene expression,
CAGGS LSL Mecp2 transgenic mice were crossed with Mecp2 +/- mice (7) to
generate animals carrying the Mecp2 null allele as well as the conditional rescue
construct. Western analysis of extracts from brain, lung and spleen of transgenic
mice (CAGGS LSL Mecp2; Mecp2 -/y) failed to detect MeCP2 protein (Fig. 1C)
indicating that the LSL cassette efficiently repressed expression of the
transgene.
Brain specific activation of the rescue transgene by Cre mediated
recombination.
We crossed the Mecp2+/-; CAGGS LSL Mecp2 mice with various Cre
transgenic lines to test whether removal of the STOP cassette would result in
activation of the CAGGS Mecp2 transgene. Four different lines were used that
expressed Cre recombinase during embryogenesis (Nestin Cre and Tau Cre) or
during postnatal life (CamKinaseII Cre 93 and 159). The nestin Cre line activates
the recombinase at E 10 in precursors of neurons and glia (7, 38) whereas the
Tau Cre line activates the enzyme in postmitotic neurons (31, 39). In the
CamKinaseII Cre line 93 (C93) the recombinase is activated in the postnatal
forebrain, hippocampus, midbrain and brainstem, reaching maximum
expression at around P21 (40) whereas in the CamKinaseII Cre line 159 (C159)
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Cre starts to be expressed in forebrain only at around P15 and reaches maximal
activity at ~P30 (41). The main characteristics of the Cre lines used are
summarized in Fig. 1B.
To assess Mecp2 transgene expression we performed western blot
analysis on total brain extracts from 6 weeks old animals. As shown in Fig. 1D
(lane 1), wt mice expressed the two MeCP2 isoforms e1 and e2 at a ratio of 9 to
1 as reported previously (33, 34) whereas only the e2 form was expressed from
the CAGGS Mecp2 transgene (lanes 3 to 6). Mice carrying the Nestin (lane 3) or
the Tau transgene (lane 4) expressed MeCP2 at a similar level as wt mice
whereas C93 double transgenic animals (lane 5) had much lower MeCP2
expression. No MeCP2 protein was detected in total brain extracts from mice
carrying the C159 transgene (lane 6). We also performed western analysis on
specific sub-regions of the brain (Fig. 1E and F). The level of MeCP2 in frontal
cortex, hippocampus and cerebellum of Nestin Cre and Tau Cre mice was
similar to the level of MeCP2 in wt mice (Fig.1E). Total MeCP2 levels in animals
carrying the C93 Cre or the C159 Cre were similar or reduced, respectively, as
compared to wt mice and no expression was found in the cerebellum (Fig. 1F).
To evaluate MeCP2 expression in single cells we performed
immunohistochemical analysis on brain sections. Staining for the Neuronal-
specific Nuclear protein (NeuN) and MeCP2 was used to determine the fraction
of neurons that had activated the transgene in different brain regions. Fig. 2D
shows that CAGGS MeCP2 staining was nuclear and localized to heterochromatin
dense areas (inset ii, arrowheads) whereas NeuN showed both nuclear and
cytoplasmic staining (inset i). We quantified the number of neurons that
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expressed the Mecp2 transgene. As shown in Figs. 2 B-D, 70-90% of the
neurons expressed CAGGS MeCP2 throughout the entire brain in Nestin Cre and
Tau Cre animals. In contrast, CamKinaseII driven Cre was activated only to
specific areas of the forebrain: Cre93 and Cre159 expressed MeCP2 in ~ 50% of
frontal cortical neurons, C93 expressed MeCP2 in all regions of the
hippocampus (CA1, CA2, CA3, DG) while expression in the C159 animals was
restricted to the dentate gyrus. No MeCP2 protein was found in the cerebellum
of these mice (representative images for all 3 regions are shown as supporting
information on the PNAS web site in Fig. 5S). We also noticed some variability
between different CAGGS MeCP2 expressing cells: the majority had wt levels of
MeCP2 but ~20% of the cells had higher or lower than endogenous MeCP2 signal
(data not shown).
The results shown in figure 1 and 2 indicate that the CAGGS Mecp2
transgene was activated by all Cre transgenes though the level and the
anatomical distribution of MeCP2 expression differed between the four tested
Cre lines. In the following discussion the Mecp2 null mutant animals carrying
the CAGGS Mecp2 transgene in combination with one of the different Cre
transgenes will be referred to as "rescued" mice and the corresponding
transgene combination as "rescue transgenes".
Cre-mediated expression of MeCP2 significantly delays lethality and
progression of symptoms.
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Mecp2 null mice develop symptoms between 4-6 weeks and die around
10-12 weeks of age (7, 24). Fig. 3A shows that Nestin Cre and Tau Cre
mediated activation of Mecp2 increased the life span of Mecp2 mutants to more
than 8 months. Also, a smaller but significant increase in life span by about 4
weeks was observed when the Mecp2 transgene was activated by C93 and C159
Cre (Fig. 3B).
Mecp2 mutant animals progressively lose motor coordination starting at
4 weeks and become severely lethargic. To assess whether activation of MeCP2
would affect the progressive behavioral alterations characteristic of the disorder
we tested nocturnal activity by placing animals in cages equipped with an
infrared beam movement detector. Figs. 3C-E show the results of baseline
activity of mice at different ages. As expected there was no difference in
nocturnal activity at 4-5 weeks in any of the genotypes (3C). At 6-15 weeks of
age Mecp2 null mice were significantly less active than wt mice (3D). Rescued
mice carrying the Nestin Cre, the Tau Cre or the C93 transgenes were as active
as wt mice. C159 double rescued mice were more active than Mecp2 null mutant
mice but less active than the other genotypes. MeCP2 -/y animals (white bar)
start to deteriorate, become uncoordinated and hypoactive, while all mutant
mice carrying the rescue transgenes had nocturnal baseline activities very
similar to wt level (black bar). No Mecp2 null mutant animals survived beyond
15 weeks of age and all other genotypes showed less activity than wt mice (3E).
These results suggest that Cre mediated activation of the Mecp2
transgene significantly prolonged the life span and delayed behavioral
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deterioration. The extent of rescue was, however, directly correlated with the
time and level of Cre transgene activation. Early activation of Cre in most
neurons (Nestin Cre and Tau Cre) led to the most efficient rescue. Importantly,
postnatal activation of MeCP2 between 1-2 weeks of age by the C93 Cre driven
transgene led to a significant rescue of symptoms whereas later activation of
Cre between 2-4 weeks, as in C159, was less efficient.
Physical development and brain growth are normal in rescued animals.
In addition to motor dysfunction, Mecp2 mutant animals display
decreased brain weight, smaller neurons and become obese with age (7). Fig. 4A
shows that body weight of mutant animals carrying any rescue transgene
combination was indistinguishable from that of wild-type (black line)
littermates, while MeCP2 deficient animals tended to gain weight (red line).
Consistent with this finding, rescued animals showed no significant difference in
brain weight when compared to wild-type littermates (Fig. 4B).  Finally, no
significant decrease in neuronal cell size in hippocampus and cortex was seen in
the C93 rescued animals while Mecp2 null mutants have smaller sized neurons
(7) (Fig. 4C). Representative images from the hippocampi of these mice are
shown as supporting information on the PNAS web site in Fig. 6S.
Discussion.
An unresolved issue in Rett syndrome is whether the manifestation of
overt symptoms can be affected by restoring MeCP2 expression in postnatal
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neurons. Previous results showed that Tau promoter-driven activation of MeCP2
in post-mitotic mutant neurons prevents development of an obvious phenotype,
consistent with the conclusion that RTT is not a developmental disorder but
rather is caused by MeCP2 deficiency in mature neurons (31). However, these
experiments did not resolve the important question of whether later reactivation
of MeCP2 in postnatal life could affect the phenotype progression.  Here we
show that induction of a Mecp2 transgene in postnatal mutant animals delayed
onset of symptoms and time of death.
To achieve activation of MeCP2 in postnatal neurons we constructed a
conditionally active rescue transgene by placing a LoxP-Stop-LoxP cassette in
front of the Mecp2e2 cDNA. MeCP2 was activated by crossing the conditional
transgene into different Cre lines that induced recombination during early
development (Nestin Cre and Tau Cre), at 2 weeks (C93) or between 2-4 weeks
of age (C159). Immunohistochemistry indicated that the Nestin and Tau Cre
transgenes activated Mecp2 in all regions of the brain whereas expression of the
CamKinaseII Cre transgenes was restricted to a smaller fraction of cells in a
given region and was not detected in the cerebellum.
Mecp2 null animals are characterized by severe motor impairment and
lethargy beginning at around 4 weeks of age and death at 8-12 weeks of age.
These phenotypes were significantly delayed when the Mecp2 rescue transgenes
were activated. The extent of the rescue seemed to depend on the timing of
Mecp2 activation and on the fraction of neurons that had undergone Cre-
mediated recombination. Thus, Nestin Cre and Tau Cre-mediated MeCP2
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activation extended the life span of mutant mice to 8 months whereas the C93
and C159 transgenes extended life span by ~ 4 weeks. A significant
improvement of basal nocturnal activity was found in mutant animals carrying
the rescue transgenes. Finally, anatomical alterations typical for RTT syndrome
such as a decreased brain weight and neuronal cell size were not seen in
rescued animals.
The most important conclusion from these results is that reactivation of
MeCP2 in mutant animals even as late as 2 to 4 weeks of age can result in a
significant amelioration of RTT-like symptoms. However, full restoration of the
phenotype was not achieved with any of the rescue transgenes, even when the
transgene was activated early in development in progenitor cells (Nestin Cre) or
at a time when neurons become postmitotic (Tau Cre). Inappropriate expression
of MeCP2 probably contributed to this partial rescue. The immunohistochemical
data indicated that temporal and spatial expression of the transgene varied
considerably depending on the Cre line used with 80% of cells expressing
MeCP2 in brains of the Nestin and Tau rescued mice and only 10% expressing
MeCP2 in the brains of C159 animals. Insufficient or no activation may have
occurred in thalamus, cerebellum, brain stem and medulla (CamKinaseII Cre
lines) that may be important for the RTT phenotype. For example the cerebellum
plays an important role in the integration of sensory perception and motor
output and deficiencies in the medullar respiratory network could be the cause
of fatal breathing irregularities in Mecp2 null mice (42). Lack of expression of
Mecp2 in these areas may have contributed to the reduced motor activity and
viability of the CamKinaseII Cre rescued animals. In addition CAGGS promoter
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driven Mecp2 expression may have been inappropriate, (too low or too high) in
a given neuron, compared to wt levels. Overexpression of MeCP2 has been
shown to have detrimental effects on CNS function both in humans and mice
(31, 43-45). We note that expression of MeCP2 from the Tau locus (31) fully
rescued the phenotype yet expression of Cre from the same locus was not
sufficient to achieve complete rescue in our system. Cre mediated excision is a
stochastic event that does not happen at the same time in all cells because it
depends both on the level of Cre enzyme and the availability of the flanking
LoxP sites. This may have created mosaicism within the neuronal population.
Direct expression from the Tau locus may have resulted in a higher fraction of
neurons expressing appropriate levels of MeCP2 emphasizing the limitations of
the Cre system.
A major unresolved issue in the pathogenesis of RTT is whether the
disorder is caused by dysfunction of postnatal neurons at a time when
symptoms become apparent or whether it is a prenatal developmental disorder
with postnatal phenotypic manifestation in the CNS. Our results are consistent
with the notion that the physical deterioration of null mice can be rescued by
reactivation of MeCP2 even at an age when overt symptoms are about to
commence. This implies that newborn RTT individuals might not have
irreversible neuronal damage and that pathological alterations of neurons may
occur only later in life. If correct, this presumption would encourage developing
therapeutic strategies aimed at affecting the course of the RTT by reversing
gene expression abnormalities caused by MeCP2 deficiency. While it would be
difficult to reverse a mutation in the Mecp2 gene it may be possible to modulate
the activity of downstream genes that have been shown to impact the phenotype
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progression, such as Bdnf (24).  Identification of such downstream genes should
further advance our understanding of the molecular basis of Rett Syndrome.
Methods.
Generation of the conditional Mecp2 LSL transgene.
We cloned a NcoI/SpeI Mecp2e2 cDNA pA fragment from (31) into pBluscript.
The CAGGS promoter (35) was inserted into the SalI-EcoRI site upstream of
Mecp2pA. The LoxP-Stop-LoxP neo resitance cassette was cloned into the EcoRI
site between the CAGGS and the Mecp2pA (36). The whole CAGGS LSL Mecp2 pA
fragment was released from pBluscript with a SalI digest, blunted and inserted
into the EcoRV sie of  pKATGfrt plasmid (37). We targeted the Cola1 locus in C10
cells (37). Hygromycin resistant ES clones were analyzed by Southern blot (37).
Positively targeted clones were injected into C57Bl/6-DBA2 blastocysts.
Chimeric offspring were bred to C57Bl/6 mice and screened for germline
transmission.
Mating schemes and genotyping.
Male mice homozygous for the LSL transgene were mated to Mecp2 +/- females
from the germline null colony (7) to obtain LSL/+; Mecp2 +/- females which
were then mated to males carrying the Cre transgene. Genotyping for the Mecp2
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locus and for the Cre was done as previously published (7, 40). Genotyping for
the Col1a1 locus was done as (24).
Isolation of frontal cortex, hippocampus and cerebellum.
For forebrain samples, the forebrain was separated from the mid- and hindbrain
by a coronal cut along the rostral border of the superior colliculi. For
hippocampus samples: the cerebellum was removed and the brains were cut
mid-sagittally; under a dissecting microscope, the anterior border of the
hippocampus was identified as the fimbria hippocampi; dorsally, the
hippocampal white matter was carefully separated from overlying cerebral
cortex along the alveus; and, finally, the subiculum was bisected in the middle
to release the hippocampal gray matter.  For brain weight analysis, brains were
freshly isolated and weighed.
Immunoblot analysis.
Organs were harvested and snap frozen in liquid nitrogen. Tissues were
homogenized with a Polytron in a lysis buffer containing 125 mM Tris and 1%
SDS (pH 6.8) supplemented with a proteinase inhibitor mix (Roche). Protein
concentrations were determined by BCA (Pierce). Sample buffer was added to a
final concentrations of 12.5% glycerol and 0.25% 2-mercaptoethanol. A total of
50 mg of protein was loaded on 4-12% Nu-Page Gel, probed with an anti-
MeCP2 rabbit polyclonal antibody (Upstate Biotechnology cat. 07-013) or anti-
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GAPDH rabbit polyclonal (Abcam) and visualized using the Amersham Pharmacia
ECL.
Immunohistochemistry.
Brains were perfused with 4% paraformaldehyde in 0.1 M phosphate buffer (pH
7.4), post-fixed in 4% paraformaldehyde overnight at 4ºC, washed in PBS,
processed by TISSUE-TEK VIP machine (Miles Scientific), and imbedded in
paraffin. Five microns serial sections were deparaffinized and treated with 10
mg/ml proteinaseK in 50mM Tris, 5mM EDTA for 10 minutes at RT. Slides were
blocked in 5% normal goat serum and incubated with anti-MeCP2 polyclonal
(23) and mouse anti-NeuN (Chemicon) at a dilution of 1:200. The primary
antibodies were detected with a Rhodamine-conjugated goat anti-rabbit IgG or
with FITC-conjugated donkey anti-mouse IgG (Jackson ImmunoResearch), both
at a dilution of 1:500. Sections were finally rinsed in PBS DAPI and mounted in
Vectashield (Vector laboratories). Images were taken with a Leica fluorescence
microscope at 40X magnification.
Nuclear size measurements.
For nuclear size measurement, brains were perfused and imbedded in paraffin
as described above. Four microns serial coronal sections were prepared and
stained as described above. Digital pictures from the hippocampus (CA1-CA2)
and somatosensory cortex LV were taken and the nuclear area (arbitrary unit) of
the neuron was determined by tracing the outline of the nucleus in the DAPI
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channel, using OpenLab. Neurons were identified by NeuN staining and the
results are expressed as the fraction of NeuN positive cells that showed MeCP2
signal. Images were collected from at least 2 animals (8 weeks old) per
genotype, 200 cells per animal were counted.
Spontaneous activity measurements.
Motor activity was measured using an infrared beam-activated movement-
monitoring chamber (Opto-Varimax-MiniA, Columbus Instruments). For each
experiment, a mouse was placed in the chamber at least 3h before recordings
started. Movement was monitored during the normal 12h dark cycle (7 p.m. to 7
a.m.). A total of 7 wt mice, 4 transgenic controls, 4 NestinCre, 4 Tau Cre, 7
CamkII93 Cre and 5 CamkII159 Cre double transgenic mice were used. One dark
cycle per animal per time point was collected.
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Figure Legends.
FIG.1  Schematic representation of the rescue construct.
A. Mecp2e2 cDNA (white box), CAGGS promoter (dark grey box), stop cassette
(light grey box), LoxP sites (black boxes). The construct was targeted to the
Col1a1 locus. Expression of Cre will loop out the stop cassette allowing the
expression of MeCP2e2. B  Characteristics of the Cre lines used. C.  Western blot
analysis of tissue from wt (lanes 1), transgenic (CAGGS LSL Mecp2; Mecp2 -/y,
lanes 2) and Mecp2 -/y (KO) mice (lane 3). No MeCP2 signal was detected in
brain, lung and spleen of null animals containing the CAGGS LSL Mecp2
transgene. Anti-GAPDH as loading control. D. Western blot of total brain
extracts of 6 weeks old animals.  Lane 1, endogenous MeCP2 in wt brain. The
higher, stronger band corresponds to MeCP2e1 and the lower fainter band
corresponds to the MeCP2e2. Lane2: Mecp2 -/y (KO); CAGGS LSL Mecp2. Lane
3,4: Nestin and Tau Cre rescued animals respectively. Lane 5-6: C93 and C159
rescued mice. E-F.  Western blot analysis of CAGGS MeCP2 expression in cortex
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(Co), hippocampus (Hi) and cerebellum (Ce). Tau and Nestin Cre activate the
transgene in all areas (E, lanes 4 to 9) while C93 and C159 activate Mecp2 in
cortex and hippocampus (F, lanes 4, 5,7 and8) but not in cerebellum (F, lanes 6
and 9). E, F lanes 1-3: endogenous MeCP2.
FIG.2 Expression of the CAGGS Mecp2 in different areas of the brain.
A. LV cortical neurons from a C93 rescued animal. CAGGS MeCP2 localizes in
heterochromatin rich areas of the nucleus (arrowheads in inset ii). NeuN
(Neuronal Nuclear-specific marker in green (i) and MeCP2 in red (ii), merge (iii).
B-D. Percentage of neurons expressing CAGGS MeCP2. For each genotype (mice
were at least 3 months old) we analyzed LV of the cortex (M1-S1) (2B),
hippocampal CA1/ CA2 boundary (2C) and cerebellum (2D). Nestin (N) and Tau
Cre (T) rescued animals expressed MeCP2 in 70 to 90% of neurons in all brain
regions surveyed. C93  rescued mice had MeCP2 expression in 50% of the
neurons in cortex and hippocampus. C159 rescued mice had maximum
expression in the cortex (60% of neurons), but little or no expression elsewhere.
No MeCP2 positive cells were found in the cerebellum of C93 and C159 rescued
animals. In wt mice 100% of neurons express MeCP2 while no expression was
observed in Mecp2 -/y mice (data not shown). At least 100 cells per animal were
included in the count. "n" is the number of animals analyzed for each genotype.
FIG.3 Rescued animals have higher probability of survival than  Mecp2 null
littermates.
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Kaplan-Meier survival curves were generated by plotting the percentage of live
mice (Y axis) against number of days after birth (X axis). "n": number of animals
analyzed. A. Nestin (N) and Tau (T) Cre double transgenic animals lived up to
280 days while control mice died within 106 days after birth. B. C93 and C159
mice lived up to 140 and 160 days, respectively. (C159 vs. null: log rank test
p=0.0431; C93 vs. C159 p=0.725). C-E. Spontaneous nocturnal activity was
measured by placing the animals in cages equipped with a movement detector
(infrared beam). On the Y axis the number of beam interruptions over 10 hours,
each bar represents a different genotype. Animals were monitored before 5
weeks (C), during the symptomatic stage (5 to 15 weeks) (D), and later than 15
weeks (E). No significant difference between wt (black bar), mutant (white bar)
and rescued mice was found in animals younger than 4 weeks of age. Between 5
and 15 weeks of age the Mecp2 mutant animals became hypoactive while
rescued animals maintained normal levels of activity. At later age (E) the rescued
animals showed lower activity that wt controls. Wt, KO, N, T, C93, C159 as in
3A-B
FIG.4 Rescued animals have normal physical development and brain weight.
A. Body weight in grams. We followed the weight of wt (black line) and rescued
animals and found no significant difference, while null mutants animals (red
line) became overweight starting at 5 weeks. By 8 weeks they were significantly
overweight compared to wt and rescued subjects. Nestin Cre*: purple line (n=4),
Tau Cre*: yellow line (n=3), C93*: green line (n=5), C159*: blue line (n=5), wt :
black line (n=4), KO*: red line (n=4) (*Mecp2 -/y; CAGGS LSL Mecp2). B. Brain
weights in grams. White circles represent wt and red triangles represent Mecp2
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null (*) brains. Green and yellow squares represent brains from C93 (*) rescued
animals and Tau Cre * rescued animals, respectively. Paired t-test wt vs.
transgenic p= 0.000110 (using the first 4 time points); wt vs. C93 p= 0.0788 C.
Neurons of C93 double transgenic animals have a normal nuclear size. Two
months old C93 Cre double transgenic (grey bar), control wt (black bar) and null
transgenic (white bar) littermates were analyzed for the comparison. Images
were taken from the primary motor cortex (layer V) at 40X magnification and
measurements from at least 200 cells were used for each bar. The animals used
for the analysis were 8 weeks old. Wt, KO, C93 as described above.
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Figure 1.  Schematic representation of the rescue construct.
A. Mecp2e2 cDNA (white box), CAGGS promoter (dark grey 
box), stop cassette (light grey box), LoxP sites (black boxes). 
The construct was targeted to the Col1a1 locus. Expression 
of Cre will loop out the stop cassette allowing the expression 
of MeCP2e2. B  Characteristics of the Cre lines used. C.  
Western blot analysis of tissue from wt (lanes 1), transgenic 
(CAGGS LSL Mecp2; Mecp2 -/y, lanes 2) and Mecp2 -/y (KO) 
mice (lane 3). No MeCP2 signal was detected in brain, lung 
and spleen of null animals containing the CAGGS LSL Mecp2 
transgene. Anti-GAPDH as loading control. D. Western blot 
of total brain extracts of 6 weeks old animals.  Lane 1, 
endogenous MeCP2 in wt brain. The higher, stronger band 
corresponds to MeCP2e1 and the lower fainter band corre-
sponds to the MeCP2e2. Lane2: Mecp2 -/y (KO); CAGGS LSL 
Mecp2. Lane 3,4: Nestin and Tau Cre rescued animals 
respectively. Lane 5-6: C93 and C159 rescued mice. E-F.  
Western blot analysis of CAGGS MeCP2 expression in cortex 
(Co), hippocampus (Hi) and cerebellum (Ce). Tau and Nestin 
Cre activate the transgene in all areas (E, lanes 4 to 9) while 
C93 and C159 activate Mecp2 in cortex and hippocampus (F, 
lanes 4, 5,7 and8) but not in cerebellum (F, lanes 6 and 9). E, 
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Figure2. Expression of the CAGGS Mecp2 in different areas of the 
brain. A. LV cortical neurons from a C93 rescued animal. CAGGS 
MeCP2 localizes in heterochromatin rich areas of the nucleus 
(arrowheads in inset ii). NeuN (Neuronal Nuclear-specific marker 
in green (i) and MeCP2 in red (ii), merge (iii). B-D. Percentage of 
neurons expressing CAGGS MeCP2. For each genotype (mice were 
at least 3 months old) we analyzed LV of the cortex (M1-S1) (2B), 
hippocampal CA1/ CA2 boundary (2C) and cerebellum (2D). Nestin 
(N) and Tau  Cre (T) rescued animals expressed MeCP2 in 70 to 
90% of neurons in all brain regions surveyed. C93  rescued mice 
had MeCP2 expression in 50% of the neurons in cortex and hippo-
campus. C159 rescued mice had maximum expression in the 
cortex (60% of neurons), but little or no expression elsewhere. No 
MeCP2 positive cells were found in the cerebellum of C93 and 
C159 rescued animals. In wt mice 100% of neurons express MeCP2 
while no expression was observed in Mecp2 -/y mice (data not 
shown). At least 100 cells per animal were included in the count. 
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Figure 3. Rescued animals have higher probability of survival than  Mecp2 null 
littermates. Kaplan-Meier survival curves were generated by plotting the percent-
age of live mice (Y axis) against number of days after birth (X axis). "n": number of 
animals analyzed. A. Nestin (N) and Tau (T) Cre double transgenic animals lived up 
to 280 days while control mice died within 106 days after birth. B. C93 and C159 
mice lived up to 140 and 160 days, respectively. (C159 vs. null: log rank test 
p=0.0431; C93 vs. C159 p=0.725). C-E. Spontaneous nocturnal activity was mea-
sured by placing the animals in cages equipped with a movement detector 
(infrared beam). On the Y axis the number of beam interruptions over 10 hours, 
each bar represents a different genotype. Animals were monitored before 5 weeks 
(C), during the symptomatic stage (5 to 15 weeks) (D), and later than 15 weeks (E). 
No significant difference between wt (black bar), mutant (white bar) and rescued 
mice was found in animals younger than 4 weeks of age. Between 5 and 15 weeks 
of age the Mecp2 mutant animals became hypoactive while rescued animals main-
tained normal levels of activity. At later age (E) the rescued animals showed lower 
















































Figure 4. Rescued animals have normal physical development and brain 
weight. A. Body weight in grams. We followed the weight of wt (black line) 
and rescued animals and found no significant difference, while null mutants 
animals (red line) became overweight starting at 5 weeks. By 8 weeks they 
were significantly overweight compared to wt and rescued subjects. Nestin 
Cre*: purple line (n=4), Tau Cre*: yellow line (n=3), C93*: green line (n=5), 
C159*: blue line (n=5), wt : black line (n=4), KO*: red line (n=4) (*Mecp2 
-/y; CAGGS LSL Mecp2). B. Brain weights in grams. White circles represent 
wt and red triangles represent Mecp2 null (*) brains. Green and yellow 
squares represent brains from C93 (*) rescued animals and Tau Cre * res-
cued animals, respectively. Paired t-test wt vs. transgenic p= 0.000110 
(using the first 4 time points); wt vs. C93 p= 0.0788 C. Neurons of C93 
double transgenic animals have a normal nuclear size. Two months old C93 
Cre double transgenic (grey bar), control wt (black bar) and null transgenic 
(white bar) littermates were analyzed for the comparison. Images were 
taken from the primary motor cortex (layer V) at 40X magnification and 
measurements from at least 200 cells were used for each bar. The animals 
used for the analysis were 8 weeks old. Wt, KO, C93 as described above.






























Figure 5S. Expression of the CAGGS Mecp2 in different areas of the brain. 
A-C. Representative images from primary somatosensory cortex layer V 
(2A), hippocampal CA1/CA2 boundary (2B) and cerebellum (2C) of wt ani-
mals (a, b, c,), Tau Cre (d,e,f)  C93 Cre (g, h, i) and C159 (l, m. n) rescued 
animals. Sections were stained for NeuN (Neuronal Nuclear-specific 
marker in green (a, d, g, l) and for MeCP2 in red (b, e, h, m). Merge of the 




Figure 6S. Neurons of C93 double transgenic animals have a normal 
nuclear size. Images from the hippocampus (dentate gyrus) of wt, KO*, 
and C93* rescued animals. Nuclei were visualized with haematoxylin 
and eosin stain. (*Mecp2 -/y; CAGGS LSL Mecp2)
93
Chapter 3
“Insulin growth factor 1 derived peptide partially rescues Rett-like
symptoms in MeCP2 mutant mice”
Emanuela Giacometti1*, Daniela Tropea2*, Nathan R. Wilson2*,
Dong Dong Fu1, Ruth Flannery1, Mriganka Sur2#, Rudolf Jaenisch1,3#
1Whitehead Institute for Biomedical Research, 9 Cambridge Center,
Cambridge, MA 02142
2Picower Institute for Learning and Memory and Department of Brain and
Cognitive Sciences, Massachusetts Institute of Technology, 43 Vassar
Street, Cambridge, MA 02139
3Department of Biology, Massachusetts Institute of Technology, 77
Massachusetts Avenue, Cambridge, MA 02139
* These authors contributed equally to the work.
94
Abstract::
Rett Syndrome is a severe form of X-linked mental retardation caused by
mutations in the gene coding for methyl CpG-binding protein 2 (MECP2). Here
we tested whether treatment of Mecp2 mutant mice with (1-3)IGF-1, a 3 amino
acid active fragment of insulin-like growth factor 1 (IGF-1), would affect the
severity and progression of the Rett-like disease. Mecp2 mutant mice exhibited
reduced synaptic potentials and persistent cortical plasticity indicative of
immature synapses, along with decreased levels of the postsynaptic protein
PSD-95 in cortical neurons. We show that systemic treatment with (1-3)IGF-1
extends life span, improves locomotor function and partially restores the
reduced synaptic function and delayed maturation. In addition, the
PI3K/Akt/PSD-95 pathway is significantly up-regulated in treated mice. Our
results suggest (1-3)IGF-1 as a strong candidate for pharmacological treatment
of Rett Syndrome and potentially of other CNS disorders caused by delayed
synapse maturation.
Introduction:
Rett Syndrome is an X-linked neurological disorder that affects 1 in
10,000-15,000 live births1. The disorder is characterized by seemingly normal
postnatal development followed by a sudden growth deceleration associated
with progressive loss of acquired motor and language skills, stereotypic hand
movements, muscle hypotonia, autonomic dysfunctions and severe cognitive
impairment. Patients live into adulthood but are severely debilitated and require
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full-time care. Unfortunately, there is no specific treatment for Rett Syndrome
and management is mainly symptomatic and individualized.
The causative mutation in 85% of Rett patients resides on the gene
coding for methyl CpG-binding protein 2 (MECP2)2. MeCP2 is thought to act as a
global transcriptional silencer through selective binding to CpG-methylated
sequences in the promoters of its target genes and subsequent recruitment of
the Sin3A silencing complex3. While expressed in many tissues, it is strongly
expressed in the central nervous system (CNS) following the onset of neuronal
maturation and synaptogenesis4,5. Three mouse models with either absent6,7 or
truncated8 MeCP2 have now been generated, and genetic experiments in these
models have confirmed that the postnatal CNS-specific deletion of Mecp2 is
sufficient to cause Rett-like symptoms9. Reciprocally, the expression of MeCP2
protein in null mice even at a very late stage of the disease can rescue the
phenotype10,11. Much effort has been directed at identifying the genes mis-
regulated in the absence of MeCP212, and until now the best characterized target
of MeCP2 regulation is the brain derived neurotrophic factor BDNF13. MeCP2-
null mice have lower levels of BDNF than wild type, and over-expression of
BDNF relieves a host of symptoms in MeCP2-null mice14, as well as in other
models of CNS disorders15,16. However, despite this protein’s potentially versatile
therapeutic applications, non-invasive (intravenous or intra-peritoneal)
administration of BDNF is hampered by its poor efficiency in crossing the brain
capillary endothelial wall (the blood–brain barrier).
A second pleiotrophic growth factor with similar promise in CNS therapy,
and the additional ability to cross the blood-brain barrier, is insulin-like growth
factor 1 (IGF-1). IGF-1 is widely expressed in the CNS during normal
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development, predominately by neurons17, and  studies of IGF-1 null and over-
expressing mice have demonstrated that this molecule, similar(ly) to / as with
BDNF, strongly promotes neuronal cell survival, synaptic maturation and
function18. Moreover, IGF-1 is a modulator of functional plasticity in the
developing cortex19, and shares key intersecting intracellular pathways with
BDNF such as the PI3K/Akt pathway20. The biological action of IGF-1 is mediated
by the binding of IGF binding proteins (IGFBP 1-6) which modulate IGF-1’s half
life and affinity for the IGF-1 receptor. Interestingly, Itoh et al. recently reported
that the binding protein IGFBP3 is a target of MeCP2 regulation that is up-
regulated in MeCP2 null mice and Rett patients21. IGF-1 is cleaved by acid
proteases into 2 peptides: (des)-IGF-1, and the N-terminal tri-peptide glycine-
proline-glutamate, (1-3)IGF-121. Of these products, (1-3)IGF-1 is of particular
interest as it crosses the blood brain barrier more efficiently than IGF-122 while
retaining strong neuro-protective efficacy23-25. Thus, given a) the established
attractiveness of BDNF for the treatment of Rett Syndrome, b) the similarity of
BDNF and IGF-1 in promoting neuronal and synaptic growth and survival, and c)
the ability of IGF-1 and in particular (1-3)IGF-1 to cross the blood-brain barrier,
we decided to investigate the ability of (1-3)IGF-1 to ameliorate Rett-like
symptoms in a mouse model of the disease.
Results:
(1-3)IGF-1 administration improves life span and behavioral performance
in a mouse model of Rett syndrome.
MeCP2 -/y mice develop Rett-like symptoms beginning at 4-6 weeks of
age, at which they progressively become lethargic, develop gait ataxia, have
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tremors, and die between 10 and 12 weeks of age (wild-type mice live for 1-1.5
years)7. To test the effectiveness of (1-3)IGF-1 treatment on the progression of
these symptoms, we treated MeCP2 null animals from 2 weeks of age with daily
intra-peritoneal injections of (1-3)IGF-1 (see Methods), while observing the
life-expectancy and motor activity of treated animals compared to vehicle-
injected controls. First, compared to vehicle-treated MeCP2 -/y littermates,
MeCP2 -/y mice treated with (1-3)IGF-1 (Fig. 1a) showed a ~50% increase in life
expectancy (an increase in the 0.5 probability survival rate from ca 60 days to
90 days), corresponding to a significant enhancement of survival (P = 0.54 *
10^-7, log rank test). Baseline nocturnal activity was also recorded, and results
are shown in Fig. 1b,c. Before 6 weeks, MeCP2 -/y mice did not show obvious
symptoms and there was no difference in activity between experimental groups
(42003 ± 15870 beam crossings “wt” vs. 28337 ± 13691 crossings “wt-t” vs.
32412 ± 10843 crossings “ko-v” vs. 34601 ± 12336 crossings “ko-t”; P > 0.05,
unpaired t-test; Fig. 1b). After 6 weeks however, MeCP2 -/y mice became
progressively lethargic when compared to wild type littermates, and MeCP2 -/y
animals treated with (1-3)IGF-1 showed a significant increase in activity levels
compared with MeCP2 -/y littermates treated with vehicle (46786 ± 15601
beam crossings “wt” vs. 52353 ± 18355 crossings “wt-t” vs. 27215 ± 6893
crossings “ko-v” vs. 40455 ± 21592 crossings “ko-t”; P = 4.06 * 10^-5 “wt. vs.
ko-v” and P < 0.001 “ko-v vs. ko-t”, unpaired t-test; Fig. 1c).
Effects of (1-3)IGF-1 treatment on brain weight and neuronal cell size in
the MeCP2 KO mouse.
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One of the more consistent anatomical findings in Rett syndrome patients
and MeCP2 null mice is a decreased brain weight and a reduction of soma size
in neurons of the cortex and hippocampus7. Mutant mice with either ablated
IGF-126, IGF1R mis-expression, or over-expression of IGFBPs also demonstrate
brain growth retardation27,28. Conversely, transgenic mice over-expressing IGF-1
at 2 to 4 postnatal weeks exhibit a 5% increase in brain weight29. To investigate
whether (1-3)IGF-1 treatment would also lead to a recovery of brain weight in
the MeCP2 null mice, we collected brains from all experimental groups and
measured brain weight and neuronal soma size. Following treatment with (1-
3)IGF-1 in knockout animals, we observed an ~10% increase in average brain
weight (0.41 ± 0.03 g “wt” vs. 0.42 ± 0.02 g “wt-t” vs. 0.33 ± 0.02 g “ko-v” vs.
0.36 ± 0.02 g “ko-t”; P = 4.02 * 10^-5 “wt. vs. ko-v” and P = 0.03 “ko-v vs.
ko-t”, unpaired t-test; Fig. 2a), with a modest but non-significant increase in
the soma size of pyramidal neurons in layer 5 of sensorimotor cortex treated
with (1-3)IGF-1 compared to vehicle-treated controls (20.31 ± 1.66 ?m
perimeter “wt” vs. 24.50 ± 0.85 ?m “wt-t” vs. 18.60 ± 1.11 ?m “ko-v” vs. 19.29
± 0.63 ?m “ko-t”; P = 0.19 “wt. vs. wt-t” and P = 0.62 “ko-v vs. ko-t”, unpaired
t-test; Fig. 2b,c).
Bradycardia in MeCP2-/y mice is partially rescued by (1-3)IGF-1 treatment.
Clinical and experimental evidence shows autonomic system dysfunctions
such as labile breathing rhythms and reduced baseline cardiac vagal tone in Rett
Syndrome patients30. A poor control of the feedback mechanisms that regulate
blood pressure homeostasis through the sympathetic system, for example
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hyperventilation-induced decrease in heart rate, is common in Rett patients and
can cause life threatening cardiac arrhythmias30,31. The pathogenesis of the
cardiac dysautonomia, although not well understood, suggests that immature
neuronal connections in the brainstem could be the cause. To examine heart
rate abnormalities in MeCP2 -/y mice and the effect of (1-3)IGF-1 treatment, we
monitored real time cardiac pulse rate in non-anesthetized wild type and MeCP2
-/y animals treated with vehicle or (1-3)IGF-1. Wild type mice exhibited a
regular distribution of heart rate measurements centered around 750 beats per
minute (Fig. 3a). In contrast, MeCP2 -/y mice exhibited a very irregular heart
rate, with frequent episodes of bradycardia (Fig. 3b). Treatment with (1-3)IGF-1
significantly reduced the occurrence of these episodes in MeCP2 -/y mice (Fig.
3c), as seen by aligning the cumulative distributions of heart rates observed in
the three conditions (P < 10^-50 “wt vs. ko-v” and P < 10^-50 “ko-v vs. ko-t”,
Kolmogorov-Smirnov test; n = 114347 samples from 5 mice “wt” vs. 198021
samples from 5 mice “ko-v” vs. 241251 samples from 9 mice “ko-t”; Fig. 3d).
Effects of (1-3)IGF-1 on the synaptic physiology of MeCP2 mutant mice.
Recent studies have reported that neurons across multiple brain regions
of MeCP2 -/y mice display a profound reduction in spontaneous activity as a
consequence of reduced excitatory synaptic drive14,32-34 and that this phenotype
can be rescued by overexpression of BDNF14. Similarly, acute application of an
IGF-1 derivate has been shown to elevate evoked excitatory postsynaptic
current (EPSC) amplitudes by 40% in rat hippocampal cultures35,36. To thus test
the efficacy of (1-3)IGF-1 in rescuing the MeCP2 -/y physiological phenotype,
we acquired intracellular whole cell recordings in acute brain slices, measuring
100
excitatory synaptic drive (spontaneous EPSC amplitude and frequency) in layer 5
cortical neurons (Fig. 4a). Here, EPSCs recorded from -/y animals were
significantly reduced in amplitude compared to EPSCs measured in wild-type
animals (P = 2.30 * 10^-50, Kolmogorov-Smirnov test; n = 1543 events “wt” vs.
717 events “ko-v”; Fig. 4b). The trend was partially reversed in EPSCs recorded
from MeCP2 -/y animals treated with (1-3)IGF-1, which were significantly larger
in amplitude than EPSCs from MeCP2 -/y mice treated with vehicle (P = 1.22 *
10^-9, Kolmogorov-Smirnov test; n = 717 events “ko-v” vs. 1723 events “ko-t”;
(Fig. 4b). These differences were also seen when averaging across cells (17.28 ±
1.98 pA “wt” vs. 6.82 ± 2.50 pA “ko-v” vs. 9.13 ± 2.13 pA “ko-t”; P = 0.02 “wt
vs. ko-t” and 0.04 “ko-t vs. ko-v”, unpaired t-test; n = 11 cells “wt”, 6 cells
“ko-v”, 7 cells “ko-t”; Fig. 4c). Throughout these measurements, access
resistance, leak, and cellular intrinsic excitability were also verified to be
consistent across groups (data not shown). Quantifying EPSC intervals showed a
slight increase in the interval between EPSC events (reduced EPSC frequency)
between wild-type and MeCP2 -/y animals (P = 0.04, Kolmogorov-Smirnov test;
n = 203 events “wt” vs. 113 events “ko-v”; Fig. 4d); though the EPSC frequency
were not significantly different when the mean values for individual cells from
different groups were compared (2.83 ± 0.37 Hz “wt” vs. 2.91 ± 0.80 Hz “ko-v”
vs. 3.06 ± 0.56 Hz “ko-t”; P = 0.99 “wt vs. ko-t” and 0.32 “ko-t vs. ko-v”,
unpaired t-test; n = 11 cells “wt”, 6 cells “ko-v”, 7 cells “ko-t”; Fig. 4e). Our
findings thus indicate that the reduction of excitatory synaptic drive in cortical
cells of MeCP2 -/y mice, and its partial rescue following (1-3)IGF-1 treatment,
are due in part to a change in EPSC amplitude as a consequence of a change in
the strength of the synapses mediating excitatory transmission in this region.
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MeCP2 deficiency leads to prolonged ocular dominance plasticity.
The timing of MeCP2 expression4 and recent data from rescue
experiments10,11 suggest that MeCP2 deficiency might cause incomplete brain
development and neuronal maturation37,38. In particular we hypothesized that
neuronal and synapse development might be arrested in Rett Syndrome,
consistent with the postnatal head growth deceleration and arrest of cognitive
functions in girls with Rett syndrome at an age equivalent to 12 months or
younger. To test this hypothesis we measured ocular dominance (OD) plasticity
in the visual cortex of wild type or MeCP2 mutant mice. OD plasticity is an
effective and reliable way to assess synaptic plasticity of the cortex in vivo39, and
relies on the ability of visual cortical circuitry to be modulated by unbalanced
activity from the two eyes. Visual stimulation of either eye produces a response
in the binocular portion of primary visual cortex (V1; Supplementary Fig. 1ai).
Suturing one eye for a few days during a critical period of development leads to
a reduction of synaptic drive from the closed eye, an increase of drive from the
open eye, and hence a shift in the balance of cortical response toward the open
eye40 (Supplementary Fig. 1bii-iii,d). [In wild type animals the cortical response
to the contralateral eye is dominant (Supplementary Fig. 1aii-iii,c), so that OD
plasticity is commonly measured by suturing the contralateral eye]. This form of
plasticity can be elicited in young animals (e.g., P28 mice) even with a brief
period (4 days) of monocular deprivation (MD), while the same period of MD is
unable to induce an OD shift in the cortex of mature animals (e.g., >P50 mice,
where the rearrangement of synaptic connections requires longer periods of
MD).
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We reasoned that if synaptic development was arrested in MeCP2-
deficient mice, synapses in visual cortex of adult mice would still be sensitive to
brief MD (as in Supplementary Fig. 1d). To measure cortical responses elicited
by stimulation of the eyes, we used optical imaging of intrinsic signals, a
technique which detects level of deoxygenated hemoglobin, is related closely to
neuronal activity, and is a highly sensitive and reliable measure of cortical
plasticity39,41 (see detailed description in Methods). Because adult MeCP2 -/y
mice do not tolerate the anesthetic required for this analysis, we used MeCP2
heterozygous females which develop milder symptoms. Fig. 5 shows that
indeed adult wild type mice did not show OD plasticity after 4 days of MD (Fig.
5a, black traces; Fig. 5b, “P60, wt“ and “wt MD“ bars, ODI = 0.25 “wt“ vs. 0.27
“wt MD“; N = 5 mice “wt“, 5 mice “wt MD“; P = 0.16, one-tailed t-test) while
age-matched MeCP2 mutants (+/-) showed a significant shift in the visually
driven response in favour of the open eye (Fig. 5a, purple dotted traces; Fig. 5b,
”P60, +/-“ and “+/- MD“ bars, ODI = 0.29 ± 0.06 “+/-“ vs. -0.02 ± 0.08 “+/-
MD“; N = 2 mice “+/-“, 5 mice “+/- MD“; P = 0.04, one-tailed t-test). These
results reveal the persistence of rapid synaptic plasticity following unbalanced
visual drive in the adult MeCP2 mutant visual cortex – a feature that is typical of
an immature cortex and is consistent with a deficit in synaptic maturation or
stabilization following MeCP2 deficiency.
Ocular dominance plasticity in adult MeCP2 +/- mice is prevented by (1-
3)IGF-1 treatment.
Developmental changes in OD plasticity are controlled in part by the
activation of the IGF-1 pathway, and administration of (1-3)IGF-1 can abolish
OD plasticity in wild type young mice19. We therefore tested if (1-3)IGF-1
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treatment could stabilize the prolonged OD plasticity observed in adult MeCP2
mutants. Female MeCP2 +/- mice, aged P60 or more, were monocularly
deprived for 4 days and treated concurrently with (1-3)IGF-1. Fig. 5a,b  show
that (1-3)IGF-1 treatment prevented the OD plasticity in the adult Mecp2 +/-
mice (Fig. 5a, purple and red traces; Fig. 5b, “P60, +/- MD“ and “+/- MD (1-
3)IGF-1“ bars, ODI = -0.02 ± 0.08 “+/- MD“ vs. 0.24 ± 0.02 “+/- MD (1-3)IGF-
1“; N = 5 mice “+/- MD“, 5 mice “+/- MD (1-3)IGF-1“; P = 0.01, one-tailed t-
test), suggesting that indeed (1-3)IGF-1 rapidly induces synapse stabilization or
maturation in a mouse model of Rett Syndrome.
(1-3)IGF-1 treatment activates Akt in the brain.
The biological actions of IGF-1 are mediated by the activation of multiple
signaling pathways including the phosphoinositide-3 kinase (PI3K) / Akt
pathways. To investigate whether this IGF-1 pathway is activated in the (1-
3)IGF-1 treated mice, brain tissue was collected at different time points after
intra-peritoneal injection and protein extracts were used for western blot
analysis. Fig. 6a (rows I and IV) shows an increase of phosphorylation of the
serine 473 residue of Akt in animals treated with (1-3)IGF-1 (wt-t) versus
controls (wt-v). Levels of total Akt were not affected (Fig. 6a, rows II and V). Akt
was activated one to three hours after injection (Fig. 6a, row I) and remained
upregulated for up to 24 hours (Fig. 6a, row IV). This time course suggests that
Akt activation is mediated by direct action of (1-3)IGF-1 in the brain.
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Interestingly, it has also been shown recently that BDNF, Akt and the post-
synaptic density protein 95 (PSD-95) act together in mice to induce synaptic
potentiation in visual cortical neurons42. Similarly, the application of insulin to
rat hippocampal cultures induces up-regulation of PSD-95 via activation of the
PI3k/Akt pathway43. PSD-95 is a highly abundant scaffolding protein which
critically determines the strength of excitatory synapses44. It is therefore
possible that the (1-3)IGF-1 induced potentiation of synaptic strength that we
observed (Fig. 4) is mediated by activation of the Akt/PSD-95 pathway. To test
this hypothesis, levels of PSD-95 protein were quantified by Western blot
analysis in wild type and MeCP2 null mice treated with either vehicle or (1-
3)IGF-1. As shown in Fig. 6b, MeCP2 -/y mice expressed lower than normal
levels of PSD-95 (Fig. 6b, row I, lanes 6-11) and treatment with (1-3)IGF-1
significantly increased expression of PSD-95 in these animals (Fig. 6b, row IV,
lanes 6-11). The expression levels of a presynaptic vesicle glycoprotein,
synaptophysin, remained unchanged in all groups (Fig. 6b, rows II and V),
indicating a specific effect of (1-3)IGF1 on components of postsynaptic
signaling and synaptic function. Averaging across multiple mice revealed a
similar trend, whereby MeCP2 -/y mice expressed similar levels of
synaptophysin, but significantly lower levels of PSD-95 (P = 0.02, unpaired t-
test; n = 5 mice “wt”, 6 mice “ko”; Fig. 6c), and treatment with (1-3)IGF-1 also
tended to increase expression of PSD-95 compared to treatment with a vehicle
(n = 5 mice “wt”, 6 mice “ko”; Fig. 6d). Thus, the weakening of synaptic function
characteristic of the Rett mouse model32-34, and its strengthening and
stabilization that we observed following (1-3)IGF-1 treatment appear to be
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mediated at least in part via the targeted modulation of the Akt / PSD-95
pathway.
Discussion:
In this study we provide evidence that (1-3)IGF-1 ameliorates symptoms
of Rett Syndrome in a mouse model of the disease. Several lines of evidence
support the hypothesis that MeCP2 mutant animals display features of immature
circuitry in the CNS that persist into adulthood. First, visual cortex connections
in adult MeCP2+/- mice display synaptic changes following monocular
deprivation usually characteristic of young mice. Second, single neurons and
synapses show a reduction in excitatory postsynaptic currents, indicating
immaturity or instability of synaptic contacts. Third, PSD-95, a marker of mature
functional synapses and their strength, is down-regulated in MeCP2 null brains.
Meanwhile, treatment with the IGF-1 derivative (1-3)IGF-1 rescues these
phenotypes, in a manner that is compatible with activation of the Akt / PSD-95
pathway and consequent fostering of synaptic stabilization. Systemic application
of (1-3)IGF-1 also significantly improves life expectancy and baseline nocturnal
activity in MeCP2 -/y mice. Furthermore, (1-3)IGF-1 relieves some of the
autonomic dysfunctions characteristic of MeCP2 deficiency such as bradycardia.
Rett Syndrome is characterized by decreased brain weight, delayed
physical development, autonomic dysfunctions and hypoactivity; over-
expression of a neurotrophic factor in the mouse model has been shown to
relieve some aspects of the disease progression14. IGF-1 is widely expressed in
the central nervous system (CNS) during normal development17 and strongly
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promotes neuronal cell survival, synaptic maturation and function. The absence
of the IGF-1 gene during murine brain development results in smaller cells with
fewer processes26 and in humans is associated with mental retardation45. After
treating MeCP2 null animals with (1-3)IGF-1 or vehicle we found a substantial
improvement in life expectancy and basal nocturnal activity in the (1-3)IGF-1
treated group. Although these effects were highly significant, it is important to
stress that MeCP2 -/y mice treated with (1-3)IGF-1 still develop the full range
of symptoms and die prematurely. The disease progression in mice, like in
patients, involves an almost asymptomatic early period followed by a
progressive deterioration from 4 to 8 weeks with death occurring usually
between 10 and 12 weeks. (1-3)IGF-1 treated mice develop symptoms at the
same age as vehicle treated controls but live significantly longer and maintain
increased activity during the later phase of the disease. IGF-1 levels normally
decrease with age, and artificially increasing levels of IGF-1 in rodents and
humans has been associated with decreased muscle loss and improved
mobility46. A similar effect might be mediated by (1-3)IGF-1 and might result in
facilitated access of (1-3)IGF-1 treated mice to food and water. Figure 2 shows
that (1-3)IGF-1 treatment significantly increases brain weight in MeCP2 -/y
mice, and bigger neuronal soma size partially accounts for this effect. It is
possible that (1-3)IGF-1 treatment also increases dendritic outgrowth or adult
neurogenesis47,48, further contributing to the overall increase in brain weight.
Our results constitute the first functional evidence for the persistence of an
immature state of cortical connections in the adult MeCP2 +/- brain. Female
MeCP2 mutant mice have an almost normal life span (8-10 months), and
develop milder symptoms much later in life than male mutant mice. The
107
pronounced effect on synaptic plasticity observed in the MeCP2 mutant female
brain was therefore rather unexpected. Due to random X inactivation,
approximately 50% of neurons in the brains of female MeCP2 +/- mice express
wild type MeCP2 protein. This would argue for a dominant effect of the mutant
neurons on the entire synaptic network, consistent with the results of earlier
genetic rescue experiments, demonstrating that reactivation of MeCP2
expression in >70% of the neurons did not prevent development of symptoms in
MeCP2 -/y mice11. We speculate that (1-3)IGF-1 reduces OD plasticity in adult
mutant mice by stabilizing synaptic contacts, though it might also increase the
number of synaptic connections. It appears that (1-3)IGF-1 acts rapidly in
stabilizing synaptic contacts in the visual cortex as the mice used for the
monocular deprivation experiments were treated only for 4 days prior to the
optical imaging. We cannot exclude the possibility that (1-3)IGF-1 affects non-
neuronal cells; for example (1-3)IGF-1 treatment could increase vascular density
and glucose utilization in the brain or have additional effects in peripheral
tissues. In the experiments described, (1-3)IGF-1 was administered to the mice
via intra-peritoneal injections. It is possible that other delivery methods, such as
intravenous infusion or ventricular delivery would be more effective and
potentially could further improve the extent of rescue of the symptoms.
In conclusion we have shown that systemic delivery of (1-3)IGF-1 can
significantly improve survival and behavior in MeCP2 mutant mice. We also
provide direct evidence that MeCP2 deficiency leads to immature synaptic
function and organization which can be partially rescued by (1-3)IGF-1
administration. The CNS effect of (1-3)IGF-1 could be mediated by activation of
the PI3K/Akt/PSD-95 pathway. While further studies will be needed to unravel
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the exact mechanism of (1-3)IGF-1 action, the results presented here point to a
potential utility of (1-3)IGF-1 towards the treatment of Rett Syndrome.
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FIGURE LEGENDS:
Figure 1:  Survival and baseline activity are significantly increased in
treated animals.
A. (1-3)IGF-1 treated MeCP2 -/y mice have longer life expectancy than vehicle
treated controls. Kaplan-Meier survival curves for MeCP2 -/y mice treated
with vehicle (“ko-v”, red line) or (1-3)IGF-1 (“ko-t”, green line). The X axis
shows the days after birth, and the Y axis shows the probability of survival.
MeCP2 -/y mice treated with (1-3)IGF-1 exhibited a significantly longer life
expectancy that their vehicle treated littermates. MeCP2 -/y mice were given
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daily IP injections of (1-3)IGF-1 (0.01 mg / g body weight / day) every day
from 2 weeks of age onward. “n” is the number of mice per experimental
group.
B. (1-3)IGF-1 treatment improves locomotor function in MeCP2 null mice.
Baseline nocturnal activity was measured by placing animals in cages
equipped with a movement detector (infrared beam). The Y axis shows the
number of beam interruptions over 10 hours; each bar represents a different
experimental group. Nocturnal activity was recorded weekly between 4 and
17 weeks of age. Data from 4-5 weeks and >6 week-old mice is shown in B
and C respectively. As expected, MeCP2 -/y mice treated with vehicle (“ko-
v”, red bar), showed significantly less activity that wild type (“wt”, black bar)
littermates. MeCP2 -/y animals treated with (1-3)IGF-1 (“ko-t”, green bar)
were more active than vehicle-treated animals (“ko-v”, red bar) but not as
active as wild type littermates. Wt animals treated with (1-3)IGF-1 (“wt-t”
grey bar) were not significantly more active than wild type. “n” =  number of
animals per group, error bars represent standard deviation.
Figure 2:  (1-3)IGF-1 increases brain weight and pyramidal neuron soma
size.
A .  Postnatal (1-3)IGF-1 treatment increases brain weight. The value bars
indicate the average brain weight (at P60) of each experimental group: wild
type “wt”, wild type treated with (1-3)IGF-1 “wt-t”; MeCP2 -/y receiving
vehicle "ko-v” or treated with (1-3)IGF-1 “ko-t”. Error bars represent
standard error. “n” :number of animals per group. MeCP2 -/y mice had lower
brain weight compared to wt mice, and MeCP2 -/y mice treated with (1-
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3)IGF-1 had increased brain weight compared to vehicle-treated MeCP2 -/y
littermates.
B. Effect of postnatal (1-3)IGF-1 treatment on cell size of layer 5 neurons in
sensorimotor (S1) cortex. (1-3)IGF-1 modestly increases average soma size
in MeCP2 -/y animals compared to vehicle treated animals. “n” = number of
animals per group; at least 24 cells per animal were measured.
C. Representative images of layer 5 neurons in S1 in the 4 experimental groups.
Scale bar represents 100 ?m.
Figure 3:  (1-3) IGF-1 reduces the frequency of bradycardia in MeCP2 null
mice.
A. Pooled distribution of heart rates observed in beats per minute (bpm) in wt
animals. The Y axis depicts the total number of observations within an
experimental group for a given bpm value (X axis).
B. Heart rate in beats per minute in MeCP2 -/y animals (8 weeks old) receiving
vehicle for 6 weeks.Heart rate in beats per minute in MeCP2 -/y (8 weeks
old) animals treated with (1-3)IGF-1 for 6 weeks.
C.  Cumulative distributions of heart rate measurements in the 3 groups. The
MeCP2 -/y distribution (red) was left-shifted compared to the wild-type
distribution (blue), indicating a significant reduction in the distribution of
heart rates. The MeCP2-/y treated with (1-3) IGF1 distribution (green) was
in-between the two curves, indicating a partial rescue of the MeCP2-/y
phenotype towards a more normal wild-type distribution.
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Figure 4: Increased amplitude of synaptic currents for layer 5 pyramidal
neurons in (1-3)IGF-1 treated MeCP2 -/y animals.
A .  Representative traces from recordings of spontaneous excitatory
postsynaptic currents (EPSCs) in wild type (wt), MeCP2 -/y treated with
vehicle (ko-v), or (1-3)IGF-1 (ko-t) for two weeks. Top traces depict a
compressed view of spontaneous activity, and the bottom two traces show
individual events with an expanded scale. Mice were 28-32 days old.
B. Cumulative distributions of EPSC amplitudes, across all cells measured, in
wild type (wt), MeCP2 -/y plus vehicle (ko-v) or MeCP2 -/y plus (1-3)IGF-1
(ko-t). Distributions indicate an increased percentage of events with smaller
amplitudes in ko-v vs. wild-type. (1-3)IGF-1 treatment partially but
significantly reversed this trend.
C.  Neurons’ mean EPSC amplitude in wild-type (wt), MeCP2 -/y (ko-v), and
MeCP2 -/y treated with (1-3)IGF-1 for two weeks (ko-t). Mean EPSC
amplitude was significantly reduced in -/y neurons compared to wild-type.
Compared to ko-v animals, mean EPSC amplitude was modestly but
significantly increased in -/y animals treated with (1-3)IGF-1. All error bars
are s.e.m.
D. Distributions of intervals between EPSC events, reflecting EPSC frequency, are
subtly modified between wt, and ko-v and ko-t groups.
E. Group analysis of mean EPSC frequency across cells in each treatment does
not indicate a significant change between groups. All error bars are s.e.m.
Figure 5:  Visual cortex plasticity in adult MeCP2 heterozygous mice is
prevented by (1-3)IGF-1.
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A.  Ocular Dominance Index (ODI) distributions from individual adult animals.
Regions of analysis typically included 900-1300 pixels, and ODI values were
derived from the optical signal intensity at each pixel driven by the two eyes
(see Methods). The mean ODI value from each animal was used for the
population analyses of part B.
B. i. Adult wild type (black lines) and MeCP2 +/- mice (purple lines) either with
monocular deprivation of the contralateral eye (MD, dashed lines) or without
MD (continuous lines).
ii. Adult MeCP2 +/- mice following MD, either untreated (dashed purple line)
or treated with (1-3)IGF-1 (red continuous line). Untreated mice show a shift
in visual drive, measured by the ODI, away from the closed eye and towards
the open eye, similar to developing animals (see part B) - demonstrating
extended plasticity and indicating the persistence of immature synapses into
adulthood. (1-3)IGF-1 treatment during the period of MD abolishes this
plasticity, preserving an ocular dominance profile typical of non-deprived
animals.
C.  Mean ODI values for developing wild type mice (~P28, left) and adult wild
type mice (~P60, right). Positive ODI values indicate higher drive from the
contralateral eye while negative values indicate higher drive from the
ipsilateral eye (see part A). Wild type “wt”, wild type after monocular
deprivation “wt MD”, MeCP2 +/- “ +/-“, MeCP2 +/- after monocular
deprivation “+/- MD”, and MeCP2 +/- treated with (1-3)IGF-1 during
monocular deprivation “+/- MD-t”. After MD, visual cortex in wild type adult
animals is still dominated by the contralateral eye while in adult MeCP2+/-
mice there is severe reduction of contralateral eye drive and a shift of ODI
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towards the ipsilateral eye. Treatment with (1-3)IGF-1 in MeCP2 +/- mice
during MD prevents the ocular dominance shift towards the ipsilateral  eye.
The ODI values for P28 wild type animals were taken from Tropea et al.19.
Error bars represent standard error.
Figure 6:  Western blot analysis of total brain tissue from different
experimental groups.
A .  Time course of Akt activation in the brain following intraperitioneal
injections of (1-3)IGF-1. 8 week old wild type C57Bl6 male mice were
injected with vehicle (wt-v) (first two lanes in each row) or with (1-3)IGF-1
(wt-t), and brain tissue was collected at the time points indicated at the top
of each lane: 5 minutes to 3 hours in rows I-III and 1 to 24 hours in rows IV-
VI. An increase in p-Akt signal can be seen at 2hr from IP injection (row I,
last two lanes). Total Akt levels (row II and V) remain unchanged until 12
hours when there is a small increase (row V last two lanes). Equal loading
was controlled with GAPDH (row III and VI).
B. MeCP2-/y (ko) mice have lower levels of post-synaptic density protein 95
(PSD-95) (row I, lanes 6-11) than wild type littermates (wt) (row I, lanes 1-5).
Adult MeCP2 -/y animals injected for 2 weeks with (1-3)IGF-1 (ko-t) have
higher levels of PSD-95 than vehicle injected age-matched -/y littermates
(ko-v) (row IV lanes 6 to 11). Levels of the synaptic vesicle glycoprotein
synaptophysin (synap.) remain unchanged in all groups (row II and V). Equal
loading was controlled with actin (rows III and VI).
C-D. Quantification of the Immunoblot signal for PSD-95 and
synaptophysin across all groups. Bar graphs represents average pixel
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density across all animals in a given experimental group. The signal was
normalized to actin. Error bars represent standard deviation.
Supplementary Figure 1:  Optical imaging of intrinsic signals to measure
ocular dominance plasticity in visual cortex.
A.  Optical imaging of intrinsic signals can be used to derive the strength of
drive from each eye in primary visual cortex (V1).
 i. Visual pathway schematic, showing inputs from each eye to V1.
 i i .  Schematic of the optical imaging setup. An anesthetized mouse is
placed in front of a monitor displaying a periodic drifting bar stimulus.
The skull surface is illuminated with red light (630 nm), and imaged
with a CCD camera.
 iii. Blood vessel pattern in the binocular region of V1 (white circle) with
representative optical signal levels when the contralateral eye (left, red
signal) or the ipsilateral eye (right blue signal) is stimulated. In wild type
adult animals the signal from the contralateral eye is stronger than the
one from the ipsilateral eye.
B. Shift in ocular dominance after monocular deprivation in a young mouse.
 i. Monocular eye lid suture for 4 days.
 ii. After the lid suture is removed, each eye is stimulated in turn and visual
responses in V1 are recorded.
 i i i.  The short period of monocular deprivation causes a weakening of
inputs from the deprived contralateral eye (red) and strengthening of
inputs from the non-deprived ipsilateral eye (blue).
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C-D. Schematic of signal intensity in the binocular region of V1
when each eye is stimulated under different conditions in wild-type
animals. Red and blue circles represent intensity of optical signal driven
by the contralateral and ipsilateral eyes, respectively. Ocular Dominance
Index (ODI) distributions at right are derived from the relative strength of
drive from each eye at each pixel. Three conditions are shown: a normal
adult wild type mouse (C), a young mouse after 4 days of monocular
deprivation (D) and an adult mouse after 4 days of MD. In a wild-type
mouse, MD of the contralateral eye during development causes a shift in
the signal intensity and ODI towards the open ipsilateral eye. Such
plasticity is not seen after a similar period of MD in an adult animal.
MATERIALS AND METHODS:
Mice mating and genotyping: We used the MeCP2 germline null allele from Chen
et al.7. Genotyping was performed as in Chen et al7.
(1-3)IGF-1 treatment: For the survival measurements, the nocturnal activity
analysis and the immunoblot analysis, (1-3)IGF-1 (Bachem Biosciences #
H22468) was administered daily via intra-peritoneal injections (0.01 mg /g body
weight, vehicle = saline, 0.01% BSA). The treatment was started at P15 and
maintained throughout the course of the experiments. For intracellular
physiology experiments, the mice were injected daily (0.01 mg / g body weight,
vehicle = saline, 0.01% BSA) for 2 weeks, from P15 to P28-P32 when they were
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used for acute slice preparation. For optical imaging experiments, mice were
injected with (1-3)IGF-1 (0.02 mg / g body weight, vehicle = saline, 0.01% BSA)
daily from the day of the lid suture to the day of imaging.
Nocturnal activity measurements:  Spontaneous motor activity was measured by
using an infrared beam-activated movement-monitoring chamber (Opto-
Varimax-MiniA; Columbus Instruments, Columbus, OH). For each experiment, a
mouse was placed in the chamber at least 3 h before recordings started.
Movement was monitored during the normal 12-h dark cycle (7 p.m. to 7 a.m.).
One dark cycle per animal per time point was collected.
Soma size measurements: For nuclear size measurement, brains from 8 weeks
old animals, treated with (1-3)IGF-1 or vehicle from the P20, were perfused with
4% paraformaldehyde in 0.1 M phosphate buffer (pH 7.4), postfixed in 4%
formaline overnight at 4°C, washed in PBS, processed with a TISSUE-TEK VIP
machine (Miles Scientific, Naperville, IL), and imbedded in paraffin. 4 ?m serial
coronal sections were prepared and Nissel stained. Digital pictures from
somatosensory cortex, layer V were taken, and the size of the nuclear area of
the neuron was determined by tracing the outline of the nucleus in microns by
using OpenLab software (Improvision, Waltham, MA). Digital picture collection
and cell measurements were done blind to the genotype.
Heart rate measurements: Real time cardiac pulse rate was measured using a tail
clip sensor (Mouse OX Oximeter, Oakmont, PA). Mice were not anesthetized but
physically restrained in a fitted open plastic tube. Prior to the recording session
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the tube was placed overnight in the cages housing the experimental animals to
allow habituation. Body temperature was maintained at ~82-84°F throughout
the recording time. We recorded 3 trials of 15 minutes for each mouse, mice
were 8 weeks old and treated with either vehicle or (1-3)IGF-1 from P15.
Slice physiology preparation:  Coronal sections (300 ?m thick) at or near
sensorimotor cortex were cut in < 4°C ACSF using a Vibratome. Slices were
incubated at 37° C for 20 minutes after slicing, and at room temperature for the
remainder of the experiment. Slices were transferred to a Warner chamber and
recordings were taken from visually identified pyramidal neurons located in
layer 5. Artificial cerebral spinal fluid (ACSF) contained 126 mM NaCl, 25 mM
NaHCO3, 1 mM NaHPO4, 3 mM KCl, 2 mM MgSO4, 2 mM CaCl2, and 14 mM
dextrose, was adjusted to 315-320 mOsm and 7.4 pH, and was bubbled with
95% O2 / 5% CO2. The intracellular pipette solution contained 100 mM
potassium gluconate, 20 mM KCl, 10 mM HEPES, 4 mM MgATP, 0.3 mM NaGTP,
and 10 mM Na-phosphocreatine.
Intracellular whole-cell recordings:  Borosilicate pipettes (3-5 M?, WPI) were
pulled using a Sutter P-80 puller (Sutter Instruments). Cells were visualized with
an Achroplan 40x water-immersion lens with infrared-DIC optics (Zeiss) and
detected with an infrared camera (Hamamatsu) projecting to a video monitor.
Experiments were driven by custom acquisition and real-time analysis software
written in Matlab (Mathworks, Natick, MA) using a Multiclamp 700B amplifier
(Axon Instruments) connected to a BNC-2110 connector block and M-Series
dual-channel acquisition card (National Instruments). Gigaseal and rupture was
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achieved and whole-cell recordings were continuously verified for low levels of
leak and series resistance. For each recording, a 5 mV test pulse was applied in
voltage clamp ~10 times to measure input and series resistance. Then in current
clamp ~10 pulses (500 ms, 40-140 pA at 10 pA increments), were applied to
quantify evoked firing rates and cellular excitability. Access resistance, leak, and
cellular intrinsic excitability were verified to be consistent across groups. Finally,
spontaneous EPSCs under voltage clamp at -60 mV were sampled at 10 kHz and
low-pass filtered at 1 kHz. Analysis was performed using a custom software
package written in Matlab, with all events detected according to automated
thresholds and blindly verified for each event individually by the experimenter.
Optical imaging of intrinsic signals:
Adult (>P60) wild type (SVEV or BL6) and MeCP2 (+/-) mutant females (BL6)
were used for this experiment. The wild type control group was composed of
both wild type littermates of MeCP2 +/- females or wild type age matched SVEV
females. For monocular deprivation, animals were anesthetized with Avertin
(0.016 ml / g) and the eyelids of one eye was sutured for 4 days. Prior to
imaging, the suture was removed and the deprived eye re-opened. Only animals
in which the deprivation sutures were intact and the condition of the deprived
eye appeared healthy were used for the imaging session. For IGF-1 signaling
activation, a solution containing (1-3)IGF-1 was injected intra-peritoneally (IP)
daily for the entire period of deprivation. For the imaging sessions mice were
anesthetized with urethane (1.5 g / kg; 20% of the full dosage was administered
IP each 20-30 minutes up to the final dosage, 0.02 ml of cloroprothixene 1%
was also injected together with the first administration). The skull was exposed
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and a custom-made plate was glued on the head to minimize movement. The
skull was thinned over V1 with a dremel drill and covered with an agarose
solution in saline (1.5%) and a glass coverslip. During the imaging session, the
animal was constantly oxygenated, its temperature maintained with a heating
blanket and the eyes periodically treated with silicone oil; physiological
conditions were constantly monitored. The anesthetized mouse was placed in
front of a monitor displaying a periodic stimulus presented to either eye,
monocularly; the stimulus consisted of a drifting vertical or horizontal white bar
of dimensions 9?x72?, drifting at 9 sec/cycle, over a uniformly gray background.
The skull surface was illuminated with a red light (630 nm) and the change of
luminance was captured by a CCD camera (Cascade 512B, Roper Scientific) at
the rate of 15 frames / sec during each stimulus session of 25 minutes. A
temporal high pass filter (135 frames) was employed to remove the slow signal
noise, after which the signal was computer processed in order to extract, at
each pixel, the temporal Fast Fourier Transform (FFT) component corresponding
to the stimulus frequency. The FFT amplitude was used to measure the strength
of the visual evoked response to each eye. The ocular dominance index was
derived from each eye’s response (R) at each pixel as ODI = (Rcontra – Ripsi)/
(Rcontra + Ripsi). The binocular zone was defined as the region activated by the
stimulation of the eye ipsilateral to the imaged hemisphere, and the most
highly-activated pixels (between 900 and 1900) in response to this stimulation
were used in the analysis.
Western blot analysis: Brains were harvested and snap frozen in liquid nitrogen.
Tissues were then homogenized in a glass-glass tissue douncer in RIPA buffer
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(50 mM HEPES-KOH, pH 7.4, 40mM NaCl, 2mM NaVO4, 50mM NaF, 10 mM Na-
pyrophosphate, 10mM Na-beta-glycerophosphate, 1% Na-deoxycolate, 1% NP-
40, and 0.1% SDS) supplemented with proteinase inhibitors (Roche, Indianapolis,
IN). Protein concentrations were determined by BCA (Pierce, Rockford, IL).
Sample buffer was added to a final concentration of 12.5% glycerol and 0.25%
2-mercaptoethanol. A total of 50 g of protein was loaded on 4–12% Nu-Page
gels. The following antibodies were used: Akt (Cell Signaling #4685), p-Akt
S473 (Cell Signaling #4058), anti-PSD-95 (Cell Signaling #2507), anti-
synaptophysin (Abcam #b18008), anti-actin (Abcam #6276), anti-GAPDH
(Abcam #8485) and visualized using ECL (Amersham Pharmacia).
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Figure 1. A. IGF1R activation. Western blot analysis of brain 
tissue from wild type mice injected with vehicle (lane 1-3) or (1-
3)IGF1 (lane4-7). Equal amounts of total protein from whole 
brains extracts was used to immunoprecipitate IFGR1. IGF1R 
immunoprecipitates were blotted either with anti IGF1R (row II ) 
or with a anti phospho IGF1R  (IGF1RTy1135/1136/IRSbTyr1150/1151) 
(row I).IgG signal was used as loading control. Row IV-VI :whole brain 
extracts Lanes 4-7 show increased Akt Ser 473 phosphorilation 
compared to samples in lanes 1-3 while total Akt is unchanged: 
row IV. Row V: GAPDH was used as loading control. B-C. Time 
course of Akt activation after (1-3)IGF1 injection. Whole brain 
protein samples from (1-3)IGF1 were obtained at various time 
points indicated at the top of each lane: 5 minutes to 3hours (row 
I-IV) or 1hour to 24 hours (row V-VII) after IP injection and blot-
ted with anti PI3K p110 (row I), p-Akt (rows I,V) or total Akt (rows 
II,VI). GAPDH was used a loading control (rows IV and VII). Protein 































Figure 2. A. Baseline nocturnal activity was measured by placing ani-
mals in cages equipped with a movement detector (infrared beam). On 
the y axis the number of beam interruptions over 10 hours, each bar 
represents a different experimental group. Nocturnal activity was 
recorded weekly between 4 and 17 weeks of age. Data from 8 weeks 
old mice is shown here. As expected KO vehicle treated show signifi-
cantly less activity that wt littermates (p=8.08E-04). MeCP2 1l/y 
(KO-T) animals treated with (1-3)IGF1 were more active than MeCP2 
1l/y (KO ) mice treated with vehicle (p=5.37E-05) but not as active as 
wild type (WT) littermates (p=0.026). Wt animals treated with (1-
3)IGF1 (WT-T) were not significantly more active than wilt type vehicle 
treated(p=0.56). n is the number of animals used.
B. Kaplan-Meier survival curves for MeCP2 ko mice treated with 
vehicle (KO-V) or (1-3)IGF1 (KO-T). On the x axis the days after birth 
and on the Y axis the probably of survival. MeCP2 KO treated mice 
have a longer life expectancy that their vehicle treated litter mates 
(p=0.54e-07). MeCp22 Ko mice were given daily IP injections of (1-





























































Figure 3. A. Representative traces from recordings of spontaneous excit-
atory postsynaptic currents (EPSCs) in either wild type (WT) or knockout 
treated with vehicle (V) or (1-3) IGF-1 for two weeks.  Top traces depict a 
compressed view of spontaneous activity, and the bottom two traces show  
individual events with an expanded scale. B. Distributions of EPSC 
amplitudes,across all cells mesured, in wild type and knockout vehicle or 
(1-3) (IGF-1) trea, indiccate a increased percentage of evnets with smaller 
amplitudes (p=2.3e--5o,Kolmogorov-Smirnov) in Ko animals versus wild 
type . (1-3) IGF-1treatment partially reversed this trend (p=1.2e-
9,Kolmogorov-Smirnov) C. Mean EPSC amplitude in wild-type (n=11 cells, 5 
animals, 1543 events), untreated knockout (n=6 cells, 2 animals, 717 
events), and knockout tissue treated with (1-3) IGF-1 for two weeks (n=7 
cells, 3 animals, 1723 events).  Mean EPSC amplitude was significantly 
reduced in knockout neurons (*, P=0.02 paired t-test).  Compared to 
knockout animals, mean EPSC amplitude was mdestly increased in knockout 
animals treated with (1-3) IGF-1 (P=0.04 paired t-test).  D. Distributions of 
EPSC intervals between events, pooling equal numbers of events from each 
recorded cell, are subtly modified between WT, and KO and KO+T groups.  
WT intervals are subtly but significantly longer compared to KO and KO+T 
intervals.  E. However, group analysis of mean EPSC frequency does not 
indicate a significant change between groups.
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Figure 4. A. Brain weight.  Postnatal (1-3)IGF1treatment 
increases brain weight. The value bars indicate the average brain 
weight of each experimental group. The error bars represent the 
standard error. “n” :number of animals per group. MeCP21l/y 
treated with (1-3)IGF1  (KO-T) had an increased brain weight 
compared to vehicle treated MeCP21l/y (KO) littermates (0.355 gr 
vs 0.326 gr p=0.032). Same was observed for (1-3)IGF1 wild type 
(WT) versus vehicle treated wt mice  (WT-V)(0.421 gr vs o.410 gr 
p=0.021).  All animals were older than P60. B. Cell size.  (1-
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Figure 5. ODI mesures in MeCP2 mutant animals and controls after mon-
ocular deprivation.
 A. Representative Ocular Dominance Index (ODI) plots from the binocular 
zone of mice from the 3 experimental groups. Dotted grey line: wild type 
mice after 4 days of deprivation; straight blue line: Mecp2 mutant mice, 
deprived for 4 days, straight red line: Mecp2 mutant mice, deprived for 4 
days and treated with IGF1(1-3). Each experimental group contains data 
from at least 5 animals. B. Mean and Standard Deviation of the Ocular 
Dominance Index (ODI) for the 4 groups of mice, the bar graphs are repre-
sentative of  data collected from at least 5 animals per group. We also col-
lectedcontro data from wild type animals, non treated and non monuclraly 





































































Figure 6. A. Levels of phosphorilated Akt (row I) increases in MeCP2 -/y 
animals treated with (1-3)IGF-1. Sample westernblot on total brain extracts 
(top) and average signal quantification of at least 3 blots (bottom). “n”=total 
number of mice in each experimental group. Signal intensities were normal-
ized to the GPDH signal. Blue and red bar represents the signal quantification 
for the phospho-Akt anitbody and total Akt respectively.  B. IGF1(1-3) treat-
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Perspectives
Relevance of the over-expression model.
The data described in Chapter two show that two-three folds level of over-
expression of MeCP2 in the brain can lead to severe motor dysfunction. The
TauMeCP2 Ki/Ki mice were runted due to an impaired ability to compete with
littermates for food. Symptoms included tremors, gait ataxia, and side-to side
swaying. In our observations the symptoms were quite different from the Rett
like phenotype displayed by the Mecp2 1l/y mice. A subsequent publication by
Collins et al. using transgenic mice that over express (human) MECP2,
MeCP2(Tg1), confirmed these observations. Detailed neurobehavioral and
electrophysiological studies of the MeCP2 (Tg1) mouse demonstrated onset of
phenotypes quite different from the classical MeCP2 knock out model. These
mice displayed enhanced motor and contextual learning and enhanced synaptic
plasticity in the hippocampus during the first 10 weeks of age; after 20 weeks of
age, however, these mice developed seizures, became hypoactive and
approximately 30% of them died by 1 year [165]. These data demonstrate that
MeCP2 levels must be tightly regulated in vivo, and that even mild over
expression of this protein is detrimental. Furthermore, these results suggested
the possibility that duplications or gain-of-function mutations in MECP2 might
underlie some cases of X-linked delayed-onset neurobehavioral disorders [165].
Indeed using an X-chromosome DNA array with a resolution of 80 kb to screen
patients with suspected X-linked mental retardation (XLMR) for X-chromosomal
aberrations showed a duplication at Xq28 in a small cohort of these patients.
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Genotype-phenotype correlation pointed to the duplication of MECP2 as the
underlying cause of severe mental retardation [166].
Functional redundancy of MeCp2e1 and MeCP2e2.
The presence of two isoforms of Mecp2 with differential tissue
expression could suggest the existence of distinct functions for each isoform.
For example, the MeCP2e1 N-terminus contains a conserved serine residue that
is absent in MeCP2e2 and which could be a target of BDNF induced
phosphorylation. It may be of future interest to determine the functional
significance of differing MeCP2 N-termini by the creation of isoform-specific
gene disruptions in mice. Nevertheless the data presented in chapter one
demonstrates that MeCP2e2, which is normally expressed at very low level in the
brain, is sufficient to rescue the phenotype, arguing for a complete functional
redundancy of the two isoforms.
Transcriptional regulation of MeCP2 expression.
It has been reported previously that there is no obvious correlation
between MeCP2 protein and RNA level in adult tissues, suggesting that Mecp2
translation may be post-transcriptionally regulated [105]. The endogeous
Mecp2 sequence contains a 182 bp 5’ UTR and a highly conserved 8.5 KB 3’ UTR
with alternative (pA) polyadenylation signals. Depending on which pA is used,
either a 1.9 Kb or a 10Kb transcript is produced. The long transcript
predominates in the brain whereas the shorter form is expressed in visceral
organs and muscle [167]. In the experiments presented in chapter one, the Tau
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–Mecp2 construct did not include either of the untranslated regions and showed
an unexpectedly high expression level. Klein et al. (2007) have identified a
potential target sequence for microRNAs mediated posttranslational regulation
in the 3’UTR of the Mecp2 gene. In particular they have shown that mir132, a
CREB (camp response element binding protein) induced microRNA, is necessary
and sufficient to regulate MeCP2 protein levels in neurons. Antisense
oligonucleotide mediated reduction of mir132 causes increased expression of
MeCP2 protein (not mRNA) and interestingly it specifically increases BDNF III
transcripts levels [168].
Complete reversal of symptoms.
Chapter two presented evidence that postnatal activation of MeCP2 in the
forebrain is sufficient to significantly delay the onset of symptoms but was not
sufficient to completely rescue the phenotype. So while on one side the data
supported the hope that indeed post-natal treatment could be effective, it left
some questions unanswered. For example, in the experiments presented in
Chapter 2, the number of cells expressing the Mecp2 rescue transgene varied
between 0 to 70%, so could 100% expression lead to a complete reversal of
symptoms? Moreover the rescue transgene was activated no later than 3 weeks
after birth. This is shortly before the mice show overt symptoms. Would later
activation, 4 to 8 weeks still be effective? When is the latest time point possible?
These questions have been addressed in a recent publication by Guy et al. [164].
In this study a stop cassette flanked by LoxP sites was placed upstream of the
endogenous Mecp2 gene. To control the removal of the stop cassette and
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therefore Mecp2 gene reactivation, Guy et al. also introduced a transgene
expressing the Cre-recombinase, estrogen receptor fusion protein (cre-ER).
Upon delivery of tamoxifen (TM) the cytoplasmic Cre-Er protein translocates to
nucleus and loops out the Stop cassette allowing expression of MeCP2 at wild
type levels and in all tissues where it is normally expressed from the
endogenous promoter. Using this inducible MeCP2 deletion system Guy et al.
were able to show that reactivation of the Mecp2 gene even in a fully
symptomatic mouse leads to a complete reversal of the phenotype.
This complete reversibility is consistent with the notion that no permanent
damage at the structural and molecular levels is caused by the absence of
MeCP2. Moreover it shows that MeCP2 function is required at all times for
maintenance of mature neuron function.
Implications of the rescue experiments.
The most important implication of the rescue studies is that RS does not
cause permanent damage to the CNS structure both in terms of architecture and
anatomy but also at the molecular level. MeCP2 deficient neurons remain
proficient to carry out their normal function even at advanced stages of disease
and can resume normal activity once MeCP2 is reintroduced or once we develop
another means of intervention that will compensate for the loss of MeCP2. The
fact that MeCP2 can be re-introduced and completely rescue the RS phenotype
also means that the DNA methylation pattern that recruits MeCP2 to its correct
targets is established and maintained properly in its absence, and that all the
other cofactors or protein complexes that mediate its downstream activity are
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also present and functional. The possibility of reintroducing functional MeCP2
protein in patients through gene therapy is certainly being considered. Gene
therapy is unarguably the definitive way to treat genetic diseases. Although a
straightforward concept in theory, in practice gene therapy has proven difficult
to realize even when directed to easily accessed somatic cell systems. Gene
therapy for diseases in which the CNS is the target organ presents even greater
challenges because of fact that neurons are non-dividing cells and are difficult
to access. From the rescue experiments discussed in Chapter 1 and 2 it is clear
that to obtain a significant rescue of the phenotype it is necessary to restore
function in 60-80% of the neurons in the CNS. Moreover the expression levels
needs to be tightly regulated, as over-expression can be detrimental. In our
view, at present, the low infection efficiency and difficulty in controlling
expression level (together with significant toxicity response) are limiting factors
for the successful use of gene therapy for the cure of RS. A similar type of
argument can be made for stem cell therapy.
The pharmacological approach.
Unfortunately, there are currently no specific treatments that halt or
reverse the progression of the disorders associated with RS, and management is
mainly symptomatic and individualized, focusing on alleviating each patient’s
problems. Pharmacological approaches to managing problems associated with
RS include melatonin for sleep disturbances and several agents to control
breathing abnormalities, seizures and stereotypic movements. As shown in
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chapter 3 the mouse model could become a very helpful tool for phenotypic
screening of drugs. In our opinion this could be the most effective and short-
term approach to the development of a treatment. This is a distinctly different
approach than the biologically driven search for an understanding of the
mechanisms, but it could be equally effective. The phenotypic approach
capitalizes on the frequent finding of multiple activities in known drugs and the
a priori unpredictable nature of phenotypic screening results. One potential
issue in using the mouse model for phenotypical screens is that we cannot really
infer the degree of rescue of complex brain functions, cognition deficits and
network wiring in humans from experimentation in mice. In addition MeCP2
might have slightly different mechanism of action in humans and in mice.
Final considerations.
Two of the most revealing experiments in the recent past were done using a
mouse model underscoring the importance and usefulness of its derivation. In
the first set of experiments it has been shown that over expression of MeCP2
can be as detrimental as its absence {Collins, 2004 #144;Luikenhuis, 2004
#159}. The phenotype of mice over expressing MeCP2 is not so well
characterized, it has some similarities with phenotype of the knock out but it
also has many differences. Anyway we learned that levels of MeCP2 protein are
crucial for neuronal physiology and must be tightly regulated.  The clinical
relevance of this observation has been confirmed by the identification of male
patients with severe mental retardation that carried duplication or triplications
of the Xq28 chromosomal region {Van Esch, 2005 #102}. In the second set of
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experiments it has been shown that Rett syndrome is, at least in the mouse
model, reversible even at advanced stages of the disease {Guy, 2007 #139}. It
remains though to be better studied to which extent this reversibility is
complete. Certainly in this study the overt physical symptoms and life span were
rescued but higher cognitive functions were not tested. In this contest the
limitations of using a mouse model to study a human mental retardation
disorder might become obvious.  Another intriguing observation is that
mutations in the MeCP2 gene are present also in patients diagnosed with autism
or other forms of mental retardation, suggesting that the spectrum of
phenotypes caused by mutations in this gene goes beyond Rett syndrome.
Conversely many aspects of Rett syndrome are reminiscent of other neurological
disorders, for example the stereotypic movements, the muscle hypotonia and
awkward gait or posture resemble of Parkinson’s disease. The microcephaly and
the general physical underdevelopment resemble metabolic disorders. The
difficulties that patients have to communicate with care givers for example
reduced eye contact, unresponsiveness and anxiety are characteristic of autistic
individuals, for these reasons Rett syndrome is included by some clinicians
among the autism spectrum disorders. These similarities have led many to
speculate the existence among different neurological disorders of common
biological pathways leading to a common set of primary or secondary
manifestations. Some patients diagnosed as severe Rett syndrome variant,
characterized by untreatable seizures and early onset, have been found with a
mutation in the CDKL5 gene, and not in the MECP2 gene {Scala, 2005 #107}.
CDKL5 is a kinase which can in vitro phosphorilate MECP2 and many other
unknown proteins {Mari, 2005 #106}. The existence of shared pathways would
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make us hope that if we find the MeCP2 effector pathway and a way to interfere
with it we might learn something relevant for other CNS dysfunctions as well.
Unfortunately all the experiments designed to systematically identify genes
bound by MeCP2 or at least genes whose expression is misregulated in its
absence have not been as informative has hoped. There are two possible
explanations for this 1) MeCp2 is a global transcriptional repressor that controls
the expression a multitude of genes depending on developmental stage and
neuronal subtype. All these transcriptional changes were too many and/or too
subtle to be detected   2) MeCP2 is a local transcritption silencer that regulates
few key genes in one or more neuronal subtypes. The misregulation of these
targets might easily be lost in experimental noise when looking at whole brain
samples. To clarify this matter it would be useful to sort different neuronal
subtypes using genetic markers and repeat both RNA microarray and chromatin
immunoprecipitation experiments, although obtaining a large number of viable
cells is not always possible and might be a limiting step in the execution of
these experiments. Another informative experiment would be the targeted
deletion of Mecp2 in specific neuronal subtypes using appropriate Cre
recombinase lines. This experiment would reveal whether specific neuronal
subtypes are responsible for different aspects of the disease.
How much is Rett syndrome a cell autonomous disorder and how much is it a
neuronal cell network problem?  From the experiments in chapter 2 it is clear
that even 70% of cell expressing MeCP2 are not enough to achieve complete
rescue suggesting that the defect is cell autonomous moreover it shows that
the presence of even a minority of mutant neurons can impair the
functionality the whole network. (isn’t that in reality the same concept??)
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Given these preconditions it is difficult to imagine gene or cell therapy as
potential strategies to rescue the symptoms of MeCP2 deficiency in patients.
Conversely if the primary or secondary effects of MeCP2 deficiency converge
in one or two common signaling pathway we could think of intervening
pharmacologically. Certainly the data on BDNF and IGF1 discussed in chapter
3 would fit this explanation. The data exposed in chapter 3 show that the
beneficial effects of (1-3)IGF-1 injections could be mediated by the activation
of the PI3K pathway but they do not investigate whether this pathway is in
anyway deficient in MeCP2 null mice. It is also possible that BDNF1 and IGF1
have a generic neuroprotective effect or that activation of the PI3K pathway
juts incidentally counterbalance the loss of MeCP2. Nevertheless it is
interesting to note that, to date, the 4 molecules (BDNF {Chang, 2006 #195},
Ampakine {Ogier, 2007 #226}, (1-3)IGF1 and the corticosteroid releasing
hormone CRH) reported to affect Rett syndrome disease progression all signal
through the PI3K/Akt pathway. Ampakines are a derivative of benzoic acid
used as neuroleptics and antipsychotics that promote plasticity by facilitating
transmission at glutamatergic synapses, their action seems to be mediated in
part by increasing levels of BDNF. CRH is a polypeptide hormone and
neurotransmitter involved in stress response whose signal transduction also
relies on PI3K/Akt activation. The ability of BDNF and IGF1 to activate the PI3K
route has been discussed above. Taken together these observations, although
circumstantial, would suggest that there is at least one, major signaling
pathway whose modulation directly affects the Rett syndrome disease
progression namely the PI3K/Akt pathway. The PI3K/Akt signaling
mechanism is very well characterized in cancer biology but its importance
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and function in the brain is juts starting to be unraveled. MeCP2 is a DNA
binding molecule that recognizes epigenetic marks (CpG methylation) and
controls gene expression. Its action is essential for proper neuronal function,
possibly by controlling synaptic development/maturation. In which way
though it is not known. The PI3k/Akt pathway has also been shown to be
essential for longterm potentiation and synaptic development. Does MeCP2
action controls or relies upon the PI3k/Akt pathway activation? Further
experiment will be needed to answer these questions and to identify other
potential mechanism of MeCP2 regulation.
Albeit the studies on BDNF {Chang, 2006 #185} and on (1-3)IGF-1 over
expression come to similar results and possibly are mediated by the same
signaling pathway substantial differences exists. For example BDNF over
expression lead to a marginal improvement in life expectancy while over
expression of (1-3)IGF-1 was more effective. However over expression of
BDNF completely rescued the electrophysiological phenotype of MeCP2
deficient cortical slices whereas over expression of (1-3)IGF-1 only partially
improved it. Also the locomotor improvement in BDNF over expressing mice
was greater than in (1-3)IGF-1 mice {Chang, 2006 #185}. The comparison
between the two experiments is anyway difficult because of the different
experimental set up. BDNF was over expressed using a transgene and the
extent and localization of over expression haven’t been carefully
characterized {Chang, 2006 #185}. (1-3)IGF-1 was instead injected
systemically and there was no characterization of the amount of peptide that
reached the brain and or other organs. Moreover depending on which insulin
receptor is activated by (1-3)IGF-1 some neuronal population might be more
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sensitive to the treatment than others. It would be therefore very informative
to better characterize the molecular mechanism of action of (1-3)IGF-1. (1-
3)IGF-1) for example is known to have greater affinity than IGF1 itself for
IGFBP proteins therefore it is possible that (1-3)IGF-1 increases levels of IGF1
by competing for binding with the IGFBPs {Sizonenko, 2001 #219}. To
overcome the difficulties in interpreting the results obtained in chapter 3 it
would be informative to over express IGF1 or (1-3)IGF-1 genetically using the
same targeting strategy used to over express BDNF. In this case IGF1 would
be over expressed in neurons only at a reproducible level and in defined
regions of the brain. The localized CNS and neuronal specific over expression
might result in more efficient rescue or, conversely, in a less efficient rescue.
May be systemic injections were positively affecting peripheral organs as well.
After all, even though there is convincing evidence that CNS restricted
deletion is sufficient to cause Rett-like symptoms, the effects of deletion of
MeCP2 only in peripheral organs are not know. Moreover arguing for CNS
specific deletions using Nestin and Tau driven Cre recombinase is not entirely
correct as both promoters have considerable peripheral activity. In light of the
promiscuous binding of MeCP2 to the chromosomes and its rather wide
expression pattern it would appear to be essential for the silencing of
numerous genes in virtually every tissue. However this is difficult to reconcile
with the relatively restricted pathology of RS and a role outside of the nervous
system (CNS) cannot be excluded, since the phenotype of the mice was
analyzed primarily with regard to neuronal function, and more subtle
deficiencies outside the CNS may have been overlooked.
Surely what is emerging from the study of Rett syndrome is that DNA
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methylation and chromatin remodeling play critical roles in the regulation of
gene expression in response to neuronal activity and high cognitive functions.
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